

FORM PTO-1390 (Modified) (REV 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER <b>55908 (46322)</b>	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (IF KNOWN; SEE 37 CFR <b>09/868879</b>	
INTERNATIONAL APPLICATION NO. <b>PCT/GB99/04399</b>		INTERNATIONAL FILING DATE <b>23 December 1999</b>		PRIORITY DATE CLAIMED <b>24 December 1998</b>	
TITLE OF INVENTION <b>GLYCOSYL PHOSPHATIDYL INOSITOL SPECIFIC PHOSPHOLIPASE D PROTEINS AND USES THEREOF</b>					
APPLICANT(S) FOR DO/EO/US <b>Julian SCHOFIELD and Thomas William RADEMACHER</b>					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.</li> <li>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</li> <li>11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409).</li> <li>12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).</li> </ol>					
Items 13 to 20 below concern document(s) or information included:					
<ol style="list-style-type: none"> <li>13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>15. <input type="checkbox"/> A <b>FIRST</b> preliminary amendment.</li> <li>16. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li> <li>17. <input type="checkbox"/> A substitute specification.</li> <li>18. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</li> <li>20. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</li> <li>21. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</li> <li>22. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail</li> <li>23. <input checked="" type="checkbox"/> Other items or information: <b>PCT/RO/101; PCT/RO/105; PCT/IB/301; PCT/IB/304; PCT/IB/308; PCT/IPEA/401</b></li> </ol>					

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53(a)(2))		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
09/868879		PCT/GB99/04399		55908 (46322)	
24. The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5) ) :					
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO				\$1000.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO				\$860.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO				\$710.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)				\$690.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)				\$100.00	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$0.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	- 20 =	0	x \$18.00	\$0.00	
Independent claims	- 3 =	0	x \$80.00	\$0.00	
Multiple Dependent Claims (check if applicable).			<input type="checkbox"/>	\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$0.00	
<input type="checkbox"/> Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				\$0.00	
SUBTOTAL =				\$0.00	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$0.00	
TOTAL NATIONAL FEE =				\$0.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).			<input type="checkbox"/>	\$0.00	
TOTAL FEES ENCLOSED =				\$0.00	
				Amount to be refunded	\$
				charged	\$
a. <input type="checkbox"/> A check in the amount of _____ to cover the above fees is enclosed.					
b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. <input type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. _____. A duplicate copy of this sheet is enclosed.					
d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. <b>Credit card information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
Robert L. Buchanan Registration No. 40,927 Dike, Bronstein, Roberts & Cushman Intellectual Property Practice Group EDWARDS & ANGELL, LLP P. O. Box 9169 Boston, MA 02209 Tel. (617) 439-4444 Fax: (617) 439-4170 / 7748					
SIGNATURE					
Robert L. Buchanan					
NAME					
40,927					
REGISTRATION NUMBER					
June 22, 2001					
DATE					

<b>VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) AND 1.27 (d)) - NONPROFIT ORGANIZATION</b>			Docket No. <b>55908 (46322)</b>
Serial No. <b>09/868,879</b>	Filing Date <b>June 22, 2001</b>	Patent No.	Issue Date
Applicant/ Patentee: <b>Julian Schofield, et al.</b>			
Invention: <b>GLYCOSYL PHOSPHATIDYL INOSITOL PHOSPHOLIPASE D PROTEINS AND USES THEREOF</b>			
<p>I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:</p> <p>NAME OF ORGANIZATION: <u>University College London</u></p> <p>ADDRESS OF ORGANIZATION: <u>Gower Street</u>  <u>London WC1E 6BT</u>  <u>ENGLAND</u></p> <p>TYPE OF NONPROFIT ORGANIZATION:</p> <p><input checked="" type="checkbox"/> University or other Institute of Higher Education</p> <p><input type="checkbox"/> Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3))</p> <p><input type="checkbox"/> Nonprofit Scientific or Educational under Statute of State of The United States of America  Name of State: _____ Citation of Statute: _____</p> <p><input type="checkbox"/> Would Qualify as Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3)) if Located in The United States of America</p> <p><input type="checkbox"/> Would Qualify as Nonprofit Scientific or Educational under Statute of State of The United States of America if Located in The United States of America  Name of State: _____ Citation of Statute: _____</p> <p>I hereby declare that the above-identified nonprofit organization qualifies as a nonprofit organization as defined in 37 C.F.R. 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention described in:</p> <p><input checked="" type="checkbox"/> the specification to be filed herewith.</p> <p><input type="checkbox"/> the application identified above.</p> <p><input type="checkbox"/> the patent identified above.</p> <p>I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.</p> <p>If the rights held by the above-identified nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).</p>			

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☐ no such person, concern or organization exists.
- ☐ each such person, concern or organization is listed below.

FULL NAME \_\_\_\_\_  
ADDRESS \_\_\_\_\_

- ☐ Individual                      ☐ Small Business Concern                      ☐ Nonprofit Organization

FULL NAME \_\_\_\_\_  
ADDRESS \_\_\_\_\_

- ☐ Individual                      ☐ Small Business Concern                      ☐ Nonprofit Organization

FULL NAME \_\_\_\_\_  
ADDRESS \_\_\_\_\_

- ☐ Individual                      ☐ Small Business Concern                      ☐ Nonprofit Organization

FULL NAME \_\_\_\_\_  
ADDRESS \_\_\_\_\_

- ☐ Individual                      ☐ Small Business Concern                      ☐ Nonprofit Organization

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: \_\_\_\_\_

TITLE IN ORGANIZATION: \_\_\_\_\_

ADDRESS OF PERSON SIGNING: \_\_\_\_\_

University College London

Gower Street

London Wc1E 6BT

ENGLAND

SIGNATURE: \_\_\_\_\_

DATE: \_\_\_\_\_

15-06-01



09868879 .062201  
101 Rec'd FCIT/TO 15 MAY 2002  
10/868879

Docket No.: 55908 (46322)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Julian Schofield, et al.

EXAMINER: Not yet assigned

SERIAL NO.: 09/868,879

GROUP: Not yet assigned

FILED: June 22, 2001

FOR: GLYCOSYL PHOSPHATIDYL INOSITOL SPECIFIC PHOSPHOLIPASE  
D PROTEINS AND USES THEREOF

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, DC 20231

\*\*\*\*\*

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on May 10, 2002.

By: Patricia A. Barnes  
Patricia A. Barnes

\*\*\*\*\*

Sir:

PRELIMINARY AMENDMENT

Please amend the application as follows.

**IN THE SPECIFICATION:**

On page 47 of the application, kindly amend this application to include the attached sequence listing (pages 47 to 109). Please renumber the abstract and the claims accordingly.

USSN 09/868,879  
Julian Schofield, et al.  
Page - 2 -

**REMARKS**

Applicants submit herewith Sequence Listing substitute pages 47-109 to include a Sequence Listing as part of this Application. The substitute pages are provided in paginated and unpaginated format.


Further enclosed is a computer readable copy of the above-mentioned copy of the Sequence Listing. That copy is the same as the copy of the Sequence Listing.

Also enclosed is a Statement in Support of Filing and Submissions in Accordance with 37 CFR 1.821-1.825, in which I declare that the content of the paper and the computer readable copies of the Sequence Listing submitted in accordance with 37 CFR 1.821 (c) and (e), respectively, are the same and that the submission, filed in accordance with 37 CFR 1.821 (g) does not introduce new matter.

The Commissioner is hereby authorized to charge any fees which may be required to consider this submission to Deposit Account No. 04-1105.

Date: 10 May, 2002

Respectfully submitted,



Robert L. Buchanan  
Registration No. 40,927  
Dike, Bronstein, Roberts & Cushman  
Intellectual Property Practice Group of  
EDWARDS & ANGELL, LLP  
P. O. Box 9169  
Boston, MA 02209  
Tel. (617) 439-4444  
Fax (617) 439-4170 / 7748

Customer No.: 21874

#174767



21874

PATENT TRADEMARK OFFICE

20/PRTS

09868879 062201

09/868879  
531 Rec'd PCT. 22 JUN 2001  
PCT/GB99/04399

Glycosylphosphatidylinositol Specific Phospholipase D  
Proteins and Uses Thereof

Field of the Invention

5 The present invention relates to  
glycosylphosphatidylinositol specific phospholipase D  
(GPI-PLD) proteins and uses of these proteins, in  
particular in the treatment and diagnosis of diabetes and  
10 complications of diabetes such as insulin resistance,  
liver dysfunction, disorders involving pancreatectomies  
and conditions mediated by a product of an infectious  
organism which is capable of inhibiting GPI-PLD, such as  
septic shock. The present invention further relates to  
variant GPI-PLD polypeptides.

Background of the Invention

15 Studies have shown that a number of cell surface proteins  
are attached to the cell membrane by covalent linkage to  
a glycosylphosphatidylinositol (GPI) anchor. It has been  
20 shown that the enzyme GPI-PLD cleaves the phosphodiester  
bond linking glycosylphosphatidylinositol to phosphatidic  
acid, thereby releasing anchored proteins.

25 GPI-PLD enzymes are abundantly present in human and  
bovine serum (5-10mg/ml in human serum). US Patent No:  
5,418,147 (Huang et al) describes the purification of  
GPI-PLD from bovine liver, and the subsequent cloning of  
three GPI-PLD enzymes from bovine liver, human liver and  
30 human pancreas cDNA libraries. This patent reports the  
full length cDNA and amino acid sequences of the GPI-PLDs  
from human and bovine liver, and the partial cDNA and  
amino acid sequences of the human pancreatic form of the  
enzyme. Subsequently, the full length sequence of the  
pancreatic form of GPI-PLD was reported in Tsang et al  
35 (1992), and this enzyme has been found in cDNA libraries  
from breast, eye, spleen and tonsil. The three forms of

the enzymes are highly homologous with the predicted mature protein sequences of bovine liver GPI-PLD sharing 82% sequence identity with the human liver enzyme and 81% sequence identity with the human pancreatic enzyme. The amino acid sequences of human liver and pancreatic forms of GPI-PLD were deposited at GenBank under accession numbers L11701 and L11702 and consist of 841 and 840 amino acids respectively. The human liver and pancreatic forms of GPI-PLD share 94.6% sequence identity. The structure of GPI-PLDs is further discussed in Scallan et al, 1991.

However, despite cloning three forms of GPI-PLD, there is no suggestion in these references as to the *in vivo* role of the enzymes. Further, the only application of the enzymes suggested is in an expression system in which a heterologous protein is expressed in a host cell as a fusion with a GPI-signal peptide, leading to the heterologous protein becoming anchored to the cell membrane by a GPI anchor, where it can be cleaved off by coexpressed or added GPI-PLD.

GPI-PLD has also been isolated from human serum by Hoener et al (1992) and this form of the enzyme was found to be identical to the human pancreatic GPI-PLD apart from changes at 531 to 534 where VIGS is replaced by MLGT. This paper also showed that treatment of serum GPI-PLD with N-glycosidase F reduced the apparent molecular weight from 123 kD to 87 kD. Similarly, Li et al (1994) have shown that GPI-PLD was cleaved by trypsin into 3 fragments (2 x 40 kD and 30 kD), and Heller et al (1994) have shown that .33, .39 and 47kD species were produced, with only the N-terminal 39 kD fragment moiety showing enzyme activity after renaturation.



It has been proposed that one function of GPI-PLD enzyme is to produce inositolphosphoglycans (IPGs) by the cleavage of "free" GPIs in the plasma membrane in response to binding of a growth factor to its receptor (Rademacher et al, 1994). This role for GPI-PLD has been demonstrated in mast cells where IgE-dependent activation of these cells results in release of their granule contents, which include substances such as histamine, a mediator of the inflammatory response. In the presence of antigen, histamine is released; this release can be mimicked by addition of IPGs and is blocked by addition of anti-GPI-PLD antibodies (Lin et al, 1991).

The role of GPI-PLD in cleaving GPI-anchored proteins, and especially inositolphosphoglycans (IPGs), is examined in Jones et al (1997). However, the authors reflect the uncertainty in the art regarding the mechanism of IPG generation, noting that "The definitive activated enzyme, being a GPI-PLC or a GPI-PLD, has yet to be unequivocally identified" and that "little attention has been paid to the role of GPI-PLD as the hydrolysing enzyme".

In summary, despite the cloning of GPI-PLD enzymes and investigation as to their biochemical properties, the role of the enzyme *in vivo* or any possible medical use remains unknown.

#### Summary of the Invention

Broadly, the present invention relates to GPI-PLD for medical use, and in particular for the treatment of conditions which respond to GPI-PLD or which are characterised by reduced levels of active GPI-PLD in patients. The present invention relates in particular to the use of GPI-PLD in the treatment and diagnosis of diabetes and complications of diabetes, liver dysfunction

and disorders involving pancreatectomies, conditions mediated by a product of an infectious organism which is capable of inhibiting GPI-PLD, such as septic shock. The GPI-PLD can be the forms of the enzyme disclosed in the prior art, or the GPI-PLDs disclosed for the first time here, including GPI-PLD variants which have a reduced susceptibility to phosphorylation by cAMP dependent protein kinase (PKA).

Accordingly, in first aspect, the present invention provides GPI-PLD for use in a method of medical treatment.

In a further aspect, the present invention provides a nucleic acid molecule encoding GPI-PLD for use in a method of medical treatment.

In a further aspect, the present invention provides the use of glycosylphosphatidylinositol specific phospholipase D (GPI-PLD) for the preparation of a medicament for the treatment of conditions that respond to GPI-PLD or which are characterised by reduced levels of active GPI-PLD as compared to a normal patient.

In a first embodiment, the present invention relates to the role of GPI-PLD in diabetes and diabetic complications.

Insulin is a major anabolic hormone and has both mitogenic and metabolic effects. Whilst much effort has been directed towards study of the cascade of intracellular phosphorylation events initiated by the binding of insulin to its cell surface receptor, the signalling arm mediated by IPGs has been largely overlooked. In one aspect, the present invention is

based on the realisation that GPI-PLDs are in fact the enzymes responsible for production of IPG second messengers following the binding of insulin to its receptor. The IPGs then interact with other cellular enzymes instigating some of the metabolic effects of the hormone. In particular, diabetic complications such as insulin resistance may be caused by deficiencies in GPI-PLD. Pancreatic islet cells produce and secrete GPI-PLD, which is transported in blood complexed with apolipoprotein A1, and may therefore represent the major source of circulating enzyme.

Insulin resistance is seen in both the early stages of type I (IDDM) and type II diabetes mellitus (NIDDM). If GPI-PLD levels are depleted by the destruction of pancreatic b-cells, as is seen in streptozotocin-treated rats, then this could be an important factor in the development of insulin resistance. This in turn suggests the treatment of such patients with GPI-PLD, optionally in combination with other diabetes therapies.

In a further aspect, the present invention provides the use of GPI-PLD for the preparation of a medicament for the treatment of diabetes, and in particular insulin dependent forms of diabetes.

In a further aspect, the present invention provides the use of GPI-PLD for the preparation of a medicament for the treatment of complications of diabetes, and in particular the treatment of insulin resistance.

In a further aspect, the present invention provides a method of treating a patient having diabetes or complications arising from diabetes, the method comprising administering to the patient a therapeutically

effective amount of GPI-PLD.

In all of the above aspects, GPI-PLD can be administered alone or in conjunction with other treatments for diabetes or diabetic complications, either sequentially or simultaneously.

In a further aspect, the present invention provides a kit comprising a composition including GPI-PLD and a second composition for the treatment of diabetes.

In a further aspect, the present invention provides the use of GPI-PLD levels or the levels of a product of GPI-PLD action, for example IPG or acyl-IPG, in the diagnosis of diabetes or diabetic complications. Thus, the present invention provides a method of diagnosing diabetes or diabetic complications, the method comprising determining the presence or amount of GPI-PLD or a product of GPI-PLD action in a biological sample from a patient. This determination can help in the diagnosis or prognosis of the patient, allowing the treatment of the patient to be tailored accordingly to the patient's individual needs.

In a second embodiment, the present invention relates to role of GPI-PLD in liver dysfunction and conditions involving pancreatectomies.

Thus, in a further aspect, the present invention provides the use of GPI-PLD for the preparation of a medicament for the treatment of liver dysfunction. Preferably, the GPI-PLD is administered in combination with apolipoprotein A1.

Treatment with GPI-PLD may also be applicable for

patients with pancreatectomies and disorders associated with this state, in which case it is preferably administered with apolipoprotein A1 or another suitable carrier such as a liposome.

5

In a further aspect, the present invention provides a method of treating a patient having liver dysfunction, the method comprising administering to the patient a therapeutically effective amount of GPI-PLD.

10

In all of the above aspects, GPI-PLD can be administered alone or in conjunction with other treatments for liver dysfunction, either sequentially or simultaneously.

15

In a further aspect, the present invention provides a kit comprising a composition including GPI-PLD, and optionally apolipoprotein A1, and a second composition for the treatment of liver dysfunction.

20

In a further aspect, the present invention provides a pharmaceutical composition comprising a nucleic acid molecule encoding a GPI-PLD protein and apolipoprotein A1.

25

In a further embodiment, the present invention relates to the role of GPI-PLD in conditions mediated by a product of an infectious organism, such as septic shock.

30

Thus, in a further aspect, the present invention provides the use of GPI-PLD in the treatment of conditions mediated by a product of an infectious organism which is capable of inhibiting GPI-PLD. The GPI-PLD can be of the forms of the enzyme disclosed in the prior art, or the GPI-PLDs disclosed for the first time here. An example of such a condition includes septic shock which commonly

35

occurs following abdominal surgery, severe burns, trauma or cardiac failure. Septic shock is generally preceded by a reduction in splanchnic blood flow, resulting in ischaemia and epithelial damage on reperfusion, allowing ingress of microorganisms and subsequent sepsis.

The present invention is based on the observation that in conditions such as septic shock, endotoxin is released from the microorganisms causing sepsis, leading to the clinical symptoms of septic shock such as total organ failure and fatal shock. The endotoxins can be glycolipids released from gram negative bacteria or glycolipids such as LAM released from *Mycobacteria* such as *Tuberculosis*. Without wishing to be bound by any particular theory, these endotoxins are believed to act by inhibiting GPI-PLD.

At present, despite many attempts in the art to develop a treatment for septic shock and other related conditions, there are no approved treatments available. In particular, a reliable diagnostic test for determining whether a patient has or is at risk of developing conditions such as septic shock would be useful as an early warning of the condition and to allow timely treatment to be given.

Accordingly, in a further aspect, the present invention provides the use of GPI-PLD for the preparation of a medicament for the treatment of a condition mediated by a product of an infectious organism which is capable of inhibiting GPI-PLD.

In a further aspect, the present invention provides a method of treating a patient having a condition mediated by a product of an infectious organism which is capable of inhibiting GPI-PLD, the method comprising

administering to the patient a therapeutically effective amount of GPI-PLD.

5 In the above aspects, the product of the infectious organism is typically an endotoxin, such as the glycolipids produced by gram negative or mycobacteria mentioned above.

10 In a further aspect, the present invention provides the use of GPI-PLD or IPG levels in the diagnosis of conditions mediated by a product of an infectious organism which is capable of inhibiting GPI-PLD, and especially to the diagnosis of septic shock and/or distinguishing between different forms of septic shock.  
15 By way of example, the GPI-PLD or a product of GPI-PLD action can be determined by measuring the amount of the material and/or a characteristic activity of the material in the biological sample.

20 Thus, the present invention provides a method of diagnosing a condition mediated by a product of an infectious organism, the method comprising determining the presence or amount of GPI-PLD or a product of GPI-PLD action in a biological sample from a patient. This  
25 determination can help in the diagnosis or prognosis of the patient, allowing the treatment of the patient to be tailored accordingly to the patient's individual needs. IPGs or the acyl IPGs produced by GPI-PLD action can be used in this diagnosis as the inhibition of GPI-PLD by  
30 endotoxins is likely to cause the level of IPGs (e.g. in urine, blood etc) to drop since the GPI-PLD causes the release of IPG precursors. Thus, monitoring either or both of the level of GPI-PLD or the IPGs provides a way of assessing the likelihood of developing conditions such  
35 as septic shock or their prognosis. A determination of

the amount of GPI-PLD can be carried out using immobilised binding agents or by determining one or more of the activities associated with GPI-PLD and/or IPGs (see further below).

5

In a further general aspect, the present invention provides an expression vector comprising nucleic acid encoding GPI-PLD for use in a method of gene therapy, e.g. in the treatment of patients unable to produce sufficient GPI-PLD. The GPI-PLD encoding nucleic acid can be a sequence shown in Figures 4 to 6 or one of the known nucleic acid sequences.

In a further general aspect, the present invention provides a cell line for transplantation into a patient, wherein the cell line is transformed with nucleic acid encoding GPI-PLD, and is capable of expressing and secreting GPI-PLD. In one embodiment, the cell line is encapsulated, e.g. in a biocompatible polymer, so that the GPI-PLD produced by the cell line can be secreted into the patient, while preventing rejection by the immune system of the host. Methods for encapsulating cells in biocompatible polymers are described in WO93/16687 and WO96/31199.

25

In a further general aspect, the present invention provides a pharmaceutical composition comprising a nucleic acid molecule encoding a GPI-PLD protein.

In a further aspect, the present invention provides a pharmaceutical composition comprising a GPI-PLD protein.

35

The present invention also relates to novel GPI-PLD proteins and nucleic acid molecules, and in particular to forms of the protein having sequence differences compared



to the known human liver and pancreatic forms reported in the prior art.

5 In a further aspect, the present invention provides a substance which is an isolated polypeptide comprising a polypeptide having the amino acid sequence set out in Figure 3.

10 In a further aspect, the present invention provides isolated nucleic acid molecules encoding any one of the above polypeptides. Examples of such nucleic acid sequences are the nucleic acid sequences set out in Figures 4 to 6. The present invention also includes  
15 nucleic molecules having, for example, greater than 90% sequence identity with the nucleic acid sequences shown in these figures.

20 In further aspects, the present invention provides an expression vector comprising the above GPI-PLD proteins, nucleic acid operably linked to control sequences to direct its expression, and host cells transformed with the vectors. The present invention also includes a method of producing the above GPI-PLD proteins comprising  
25 culturing the host cells and isolating the GPI-PLD thus produced.

30 We have now also identified a phosphorylation site on GPI-PLD acted on by cAMP protein dependent kinase (PKA) which switches off the activity of the enzyme. This in turn makes it possible to make GPI-PLD variants having a reduced tendency to be phosphorylated, and consequently have an improved activity profile, and utility *in vitro* or *in vivo*.

35 Accordingly, the present invention provides variant GPI-

PLD polypeptides differing in amino acid sequence in the region corresponding to amino acid residues 689-692 (RRFS) of mature human wild-type GPI-PLD (corresponding to residues 713-716 of the sequence shown in Figure 7).

5 These proteins have a reduced tendency or cannot be phosphorylated by the PKA (which is itself activated by the A-type IPGs released by GPI-PLD), and so are likely to have increased activity or half-life when used *in vitro* or *in vivo*.

10

Thus, present invention identifies for the first time a region between amino acids 689-692 which when modified, e.g. by a substitution, deletion or insertion of one or more amino acids, disrupts the phosphorylation site in this region. Preferred modifications are substitutions, and in particular substitutions to change the serine residue at position 692 to an amino acid other than serine or threonine.

15

20

Accordingly, in a first aspect, the present invention provides a variant GPI-PLD polypeptide comprising a modification within the motif RRFS present at amino acids 689 to 692 of wild-type mature human GPI-PLD.

25

In a further aspect, the present invention provides an isolated nucleic acid molecule encoding the variant GPI-PLD polypeptide.

30

In a further aspect, the present invention provides an expression vector comprising nucleic acid encoding a variant GPI-PLD polypeptide, operably linked to control sequences to direct its expression.

35

In further aspects, the present invention provides host cells transformed with said nucleic acid encoding a GPI-

PLD variant polypeptide, and methods of producing a variant GPI-PLD polypeptide comprising culturing the host cells so that the variant GPI-PLD polypeptide is expressed and isolating the polypeptide thus produced.

5 The method may comprise the further step of then formulating the variant GPI-PLD polypeptide in a composition.

10 In a further aspect, the present invention provides the above variant GPI-PLD polypeptides or the nucleic acid molecules encoding them for use in methods of medical treatment, in particular the conditions described above.

15 In a further aspect, the present invention provides the use of a variant GPI-PLD polypeptide, or a nucleic acid molecule encoding it, for the preparation of a medicament for the treatment of conditions that respond to GPI-PLD.

20 These and other aspects of the present invention are described in more detail below.

By way of example, embodiments of the present invention will now be described in more detail with reference to the accompanying figures.

#### 25 Brief Description of the Figures

Figure 1 shows an alignment of the deduced amino acid sequences of GPI-PLD encoded by cDNA clone A1 and the bovine and human liver GPI-PLD sequences disclosed in US Patent No: 5,418,147 (Huang et al).

30 Figure 2 shows the nucleic acid sequence from cDNA clone A1 aligned with the pancreatic forms of GPI-PLD disclosed in US Patent No: 5,418,147 (Huang et al) (partial sequence) and the corresponding full length nucleic acid

35

sequence deposited at GenBank.

Figure 3 shows the amino acid sequences of the GPI-PLDs in clones a1, b2 and d3, and consist of 840, 795 and 510 amino acids respectively.

Figure 4 shows the nucleic acid sequence of cDNA clone a1 encoding GPI-PLD, consisting of 2832 bp.

Figure 5 shows the nucleic acid sequence of cDNA clone b2 encoding GPI-PLD, consisting of 2472 bp.

Figure 6 shows the nucleic acid sequence of cDNA clone d3 encoding GPI-PLD, consisting of 1942 bp.

Figure 7 shows an alignment of the deduced amino acid sequences of GPI-PLDs encoded by cDNA clones a1, b2 and d3 with the pancreatic form of the enzyme deposited at GenBank under accession number 11702.

Figure 8 shows an alignment of the nucleic acid sequences from cDNA clones a1, b2 and d3 with the cDNA sequence encoding the human pancreatic form of GPI-PLD deposited at GenBank under accession number L11702.

#### Detailed Description

##### GPI-PLD Proteins

The term "GPI-PLD biological activity" is herein defined as the enzymatic activity of GPI-PLD in cleaving the photodiester bond linking glycosylphosphatidylinositol to phosphatidic acid, e.g. releasing a GPI-anchored protein. As noted in Heller et al (1994), this activity has been localised to the N-terminal 39 kD portion of full length GPI-PLD.

The medical uses of GPI-PLD described herein can use the

novel GPI-PLD variants or the forms of the enzyme disclosed in the prior art. In either event, the skilled person can use the techniques described herein and others well known in the art to produce large amounts of these proteins, or fragments or active portions thereof, for use as pharmaceuticals, in the developments of drugs and for further study into its properties and role in vivo.

In a further aspect of the present invention provides a polypeptide having the amino acid sequence shown in Figure 3, which may be in isolated and/or purified form, free or substantially free of material with which it is naturally associated. In one embodiment, the clone a1 has an amino acid sequence consisting of 840 amino acids, a 23 amino acid signal peptide and a 817 amino acid mature protein. The present invention relates to both GPI-PLD proteins (and variants thereof) with and without the signal peptide, i.e. comprising amino acids 1-840 or 24-840 as shown in the figures.

GPI-PLD proteins which are amino acid sequence variants or alleles can also be used in the present invention. A polypeptide which is a variant or allele may have an amino acid sequence which differs from that given in Figures 1 or 3 by one or more of addition, substitution, deletion and insertion of one or more amino acids. Preferred polypeptides have GPI-PLD enzymatic function as defined above.

A GPI-PLD protein which is an amino acid sequence variant or allele of an amino acid sequence shown in Figures 1 or 3 may comprise an amino acid sequence which shares greater than about 70%, greater than about 80%, greater than about 90%, greater than about 95%, greater than about 97%, greater than about 98% or greater than about

99% sequence identity with an amino acid sequence shown in Figures 1 or 3. Sequence comparison and identity calculations were carried out using the Cluster program (Thompson et al, 1994), using the following parameters (Pairwise Alignment Parameters: Weight Matrix: pam series; Gap Open Penalty: 10.00; Gap Extension Penalty: 0.10). Alternatively, the GCG program could be used which is available from Genetics Computer Group, Oxford Molecular Group, Madison, Wisconsin, USA, Version 9.1. Particular amino acid sequence variants may differ from those shown in Figures 1 and 3 by insertion, addition, substitution or deletion of 1 amino acid, 2, 3, 4, 5-10, 10-20 20-30, 30-50, 50-100, 100-150, or more than 150 amino acids.

The variant GPI-PLD polypeptides of the present invention differ in amino acid sequence as compared to human GPI-PLD at the phosphorylation site from amino acids 689 to 692 of the mature sequence (corresponding to amino acids 713-716 shown in Figure 7), i.e. within the amino acid motif RRFS. The term 'variant GPI-PLD polypeptide' is intended, inter alia, to include polypeptides which are modified within this region by deletion, substitution and/or insertion of one or more amino acids. These sequence differences may be the result of varying the GPI-PLD amino acid sequence of a parent GPI-PLD polypeptide, either a wild type GPI-PLD polypeptide or a GPI-PLD polypeptide comprising one or more other modifications, e.g. by manipulation of the nucleic acid encoding the polypeptide, by altering the polypeptide itself or by the *de novo* synthesis of the variant protein. In preferred embodiments, the GPI-PLD retains, at least in part, one of its biological activities, e.g. by the presence of a functional N-terminal domain.

A deletion may take the form of the deletion of one, two, three or all four amino acids within the region. In some embodiments, the deletion may be part of a larger deletion encompassing a greater part of the GPI-PLD molecule. In a preferred embodiment, the variant GPI-PLD polypeptides have an amino acid sequence which differs from the amino acid sequence of human wild type GPI-PLD by the deletion comprising residues 689 to 692 inclusive.

An insertion may take the form of 1, 2, 3, 4 or 5 or more additional amino acids inserted between amino acids within the RRFS motif to disrupt it.

A substitution may take the form of the substitution of one, two, three or all of the four amino acids within the region corresponding to amino acids 689 to 692 of wild type human GPI-PLD. The substitutions within this region may be part of a more extensive series of substitutions encompassing other parts of the GPI-PLD polypeptide. In particular, mutant forms of GPI-PLD which may have practical use differ from the wild type sequence. Some of these mutants are used in the experiments described below.

In all cases, it is preferred that the resulting GPI-PLD variant retains or has an increased GPI-PLD biological activity as compared to human wild type GPI-PLD, and more especially the enzymatic activity of GPI-PLD in cleaving the photodiester bond linking GPI to phosphatidic acid, and thereby releasing a GPI-anchored protein.

The present invention also includes the use of active portions and fragments of the GPI-PLD proteins.

An "active portion" of GPI-PLD protein is a polypeptide

which is less than said full length GPI-PLD protein, but which retains at least one its essential biological activity, e.g. the enzyme activity mentioned above known to be located in the N-terminal 39kD portion of the enzyme. For instance, portions of GPI-PLD protein can act as sequestrators or competitive antagonists by interacting with other proteins.

A "fragment" of the GPI-PLD protein means a stretch of amino acid residues of at least about 5 to 7 contiguous amino acids, often at least about 7 to 9 contiguous amino acids, typically at least about 9 to 13 contiguous amino acids, more preferably at least about 20 to 30 or more contiguous amino acids, more preferably greater than 40 amino acids, more preferably greater than 100 amino acids.

A polypeptide according to the present invention may be isolated and/or purified (e.g. using an antibody) for instance after production by expression from encoding nucleic acid (for which see below). Polypeptides according to the present invention may also be generated wholly or partly by chemical synthesis. The isolated and/or purified polypeptide may be used in formulation of a composition, which may include at least one additional component, for example a pharmaceutical composition including a pharmaceutically acceptable excipient, vehicle or carrier. A composition including a polypeptide according to the invention may be used in prophylactic and/or therapeutic treatment as discussed below.

The GPI-PLD polypeptides can also be linked to a coupling partner, e.g. an effector molecule, a label, a drug, a toxin and/or a carrier or transport molecule. Techniques



for coupling the peptides of the invention to both peptidyl and non-peptidyl coupling partners are well known in the art. In one embodiment, the carrier molecule is a 16 aa peptide sequence derived from the homeodomain of *Antennapedia* (e.g. as sold under the name "Penetratin"), which can be coupled to a peptide via a terminal Cys residue. The "Penetratin" molecule and its properties are described in WO91/18981.

#### A and P-type IPGs

Studies have shown that A-type mediators modulate the activity of a number of insulin-dependent enzymes such as cAMP dependent protein kinase (inhibits), adenylate cyclase (inhibits) and cAMP phospho-diesterases (stimulates). In contrast, P-type mediators modulate the activity of insulin-dependent enzymes such as pyruvate dehydrogenase phosphatase (stimulates), glycogen synthase phosphatase (stimulates), and cAMP dependent protein kinase (inhibits). The A-type mediators mimic the lipogenic activity of insulin on adipocytes, whereas the P-type mediators mimic the glycogenic activity of insulin on muscle. Both A-and P-type mediators inhibit cAMP dependent protein kinase and are mitogenic when added to fibroblasts in serum free media. The ability of the mediators to stimulate fibroblast proliferation is enhanced if the cells are transfected with the EGF-receptor. A-type mediators can stimulate cell proliferation in the chick cochleovestibular ganglia.

Soluble IPG fractions having A-type and P-type activity have been obtained from a variety of animal tissues including rat tissues (liver, kidney, muscle brain, adipose, heart) and bovine liver. A-type and P-type IPG biological activity has also been detected in human liver and placenta, malaria parasitized RBC and mycobacteria.

The ability of an anti-inositolglycan antibody to inhibit insulin action on human placental cytotrophoblasts and BC3H1 myocytes or bovine-derived IPG action on rat diaphragm and chick cochleovestibular ganglia suggests cross-species conservation of many structural features.

A-type substances are cyclitol-containing carbohydrates, also containing  $\text{Zn}^{2+}$  ions and optionally phosphate and having the properties of regulating lipogenic activity and inhibiting cAMP dependent protein kinase. They may also inhibit adenylate cyclase, be mitogenic when added to EGF-transfected fibroblasts in serum free medium. A-type IPGs isolated from sources such as human or bovine liver have the property of stimulating lipogenesis in adipocytes. In contrast, the A-type substances from porcine tissue have the properties of inhibiting lipogenesis and lowering blood glucose levels when administered to diabetics, i.e. patients or a suitable animal model.

P-type substances are cyclitol-containing carbohydrates, also containing  $\text{Mn}^{2+}$  and/or  $\text{Zn}^{2+}$  ions and optionally phosphate and having the properties of regulating glycogen metabolism and activating pyruvate dehydrogenase phosphatase. They may also stimulate the activity of glycogen synthase phosphatase, be mitogenic when added to fibroblasts in serum free medium, and inhibit cAMP dependent protein kinase.

Methods for obtaining A-type and P-type IPGs are set out in Caro et al, 1997, and in WO98/11116 and WO98/11117.

#### Pharmaceutical Compositions

As mentioned above, GPI-PLD proteins including the variant proteins can used for treating diabetes and the

complications of diabetes (e.g. insulin resistance), optionally in conjunction with other treatments for these disorders.

5 GPI-PLD proteins can be administered alone or in combination with other treatments for diabetes or diabetic complications, either simultaneously or sequentially. Examples of known diabetes treatments include (a) insulin, which is typically delivered by  
10 injection, (b) oral insulin compositions, (c) glucose sparing or insulin enhancing drugs, (d)  $\alpha$ -glucosidase inhibitors to reduce carbohydrate absorption (precose and miglitol), and (e) drugs used to treat patients with insulin sensitivity, e.g. thiazolidinediones, such as  
15 Rezulin, rosiglitazone, pioglitazone and tyrosine phosphatase inhibitors.

In further embodiments, the GPI-PLD can be administered with P and/or A-type IPGs, and/or antagonists of these  
20 substances. Methods for obtaining A-type and P-type IPGs and their antagonists are set out in Caro et al, 1997, and in WO98/11116 and WO98/11117.

The role of P and A-type IPGs and their use in the  
25 diagnosis and treatment of diabetes is disclosed in WO98/11435. In summary, this application discloses that in some forms of diabetes the ratio of P:A type IPGs is imbalanced and can be corrected by administering a medicament comprising the appropriate ratio of P or A-  
30 type IPGs or antagonist thereof. In particular, WO98/11435 describes the treatment of obese type II diabetes (NIDDM) patients with a P-type IPG or with an A-type IPG antagonist, such as antibodies which bind specifically to the A-type IPG, and the treatment of IDDM  
35 or lean type II diabetes (NIDDM) (body mass index < 27)

with a mixture of A and P-type IPGs, typically in a P:A ratio of about 6:1 for males and 4:1 for females.

5 The compositions of the invention can be used in the treatment of diabetes, in particular insulin dependent forms of diabetes (type I and type II diabetes). They can also be used in the treatment of the complications of diabetes and in particular forms of insulin resistance such as insulin resistance in type I or type II diabetes  
10 and brittle diabetes.

In a further aspect, GPI-PLD proteins can used for treating liver dysfunction, optionally in conjunction with other treatments for these disorders. Preferably,  
15 the GPI-PLD is administered with apolipoprotein A1, and more preferably, as a complex with this substance. The isolation of apolipoprotein A1 is described in Hoener et al (1993), Deeg et al (1994) and Brewer et al (1986). The compositions can be used to treat liver dysfunction  
20 conditions which are characterised by reduced levels of apolipoprotein A1 and/or GPI-PLD and/or apolipoprotein A1/GPI-PLD complex.

GPI-PLD proteins can be administered alone or in  
25 combination with other treatments for liver dysfunction, either simultaneously or sequentially.

In a further aspect, GPI-PLD proteins and IPGs can used for treating treatment of conditions caused by a product  
30 of an infectious organism which is capable of inhibiting GPI-PLD.

As mentioned above, in further embodiments, the GPI-PLD can be administered alone or in combination with P and/or  
35 A-type IPGs.

In all of the above embodiments, the GPI-PLD proteins and any accompanying compositions can be formulated in pharmaceutical compositions, which may comprise, in addition to one of the above substances, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material may depend on the route of administration, e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.

Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may include a solid carrier such as gelatin or an adjuvant. Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as sodium chloride injection, Ringer's injection, lactated Ringer's injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included as required.

Whether it is a polypeptide, peptide, nucleic acid molecule, small molecule or other pharmaceutically useful compound of the invention that is to be given to an individual, administration is preferably in a  
5 "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this being sufficient to show benefit to the individual. The actual amount administered, and rate and time-course of  
10 administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated,  
15 the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed),  
20 1980.

#### GPI-PLD nucleic acid

"GPI-PLD nucleic acid" includes a nucleic acid molecule which has a nucleotide sequence encoding a polypeptide  
25 which includes the amino acid sequence shown in Figures 4 to 6, and in some embodiments of the invention extends to the known human liver and pancreatic forms of GPI-PLD (L11701 and L11702). These forms of GPI-PLD have been mapped to human chromosome 6 and are contained in the 4  
30 centimorgan region of D6S1660-D6S1558 at positions 95.95 and 99.71 (NCBI GeneMap'98). The gene starts in the cytogenic region corresponding to 6p22.3 and extends into 6p21.3. This region also contains the IDDM1 and HLA loci (although the HLA genes map to the adjacent D6S1558-  
35 D6S1616 interval). The mouse GPI-PLD gene has also been

mapped to chromosome 13, near the *fim 1* locus, which is found in humans on chromosome 6.

5 The GPI-PLD coding sequence may be that shown in Figures 2, 4 to 6 or 8, a complementary nucleic acid sequence, or it may be a mutant, variant, derivative or allele of these sequences. The sequence may differ from that shown by a change which is one or more of addition, insertion, deletion and substitution of one or more nucleotides of  
10 the sequence shown. Changes to a nucleotide sequence may result in an amino acid change at the protein level, or not, as determined by the genetic code.

15 The encoded polypeptide may comprise an amino acid sequence which differs by one or more amino acid residues from the amino acid sequence shown in the figures.

Nucleic acid encoding a polypeptide which is an amino acid sequence mutant, variant or allele of the sequence shown in Figures 1, 3 or 7 is further provided by the  
20 present invention. Such polypeptides are discussed below. Nucleic acid encoding such a polypeptide may show greater than about 70% identity, greater than about 80% identity, greater than about 90% identity, greater than about 95% identity, greater than about 98% identity, or  
25 greater than about 99% identity with a sequence shown in the figures.

The present invention also includes fragments of the GPI-PLD nucleic acid sequences described herein, the  
30 fragments preferably being at least 12, 15, 30, 45, 60, 120 or 240 nucleotides in length.

Generally, nucleic acid according to the present invention is provided as an isolate, in isolated and/or  
35 purified form, or free or substantially free of material

with which it is naturally associated, such as free or substantially free of nucleic acid flanking the gene in the human genome, except possibly one or more regulatory sequence(s) for expression. Nucleic acid may be wholly or partially synthetic and may include genomic DNA, cDNA or RNA. Where nucleic acid according to the invention includes RNA, reference to the sequence shown should be construed as reference to the RNA equivalent, with U substituted for T.

Nucleic acid sequences encoding all or part of the GPI-PLD gene and/or its regulatory elements can be readily prepared by the skilled person using the information and references contained herein and techniques known in the art (for example, see Sambrook, Fritsch and Maniatis, "Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989, and Ausubel et al, Short Protocols in Molecular Biology, John Wiley and Sons, 1992). These techniques include (i) the use of the polymerase chain reaction (PCR) to amplify samples of such nucleic acid, e.g. from genomic sources, (ii) chemical synthesis, or (iii) amplification in *E. coli*. Modifications to the GPI-PLD sequences can be made, e.g. using site directed mutagenesis, to provide expression of modified GPI-PLD protein or to take account of codon preference in the host cells used to express the nucleic acid.

In order to obtain expression of the GPI-PLD nucleic acid sequences, the sequences can be incorporated in a vector having control sequences operably linked to the GPI-PLD nucleic acid to control its expression. The use of expression systems has reached an advanced degree of sophistication. The vectors may include other sequences such as promoters or enhancers to drive the expression of



the inserted nucleic acid, nucleic acid sequences so that the GPI-PLD protein is produced as a fusion and/or nucleic acid encoding secretion signals so that the polypeptide produced in the host cell is secreted from the cell. GPI-PLD protein can then be obtained by transforming the vectors into host cells in which the vector is functional, culturing the host cells so that the GPI-PLD protein is produced and recovering the GPI-PLD protein from the host cells or the surrounding medium. Prokaryotic and eukaryotic cells are used for this purpose in the art, including strains of *E. coli*, yeast, and eukaryotic cells such as COS or CHO cells. The choice of host cell can be used to control the properties of the GPI-PLD protein expressed in those cells, e.g. controlling where the polypeptide is deposited in the host cells or affecting properties such as its glycosylation and phosphorylation.

PCR techniques for the amplification of nucleic acid are described in US Patent No:4,683,195. In general, such techniques require that sequence information from the ends of the target sequence is known to allow suitable forward and reverse oligonucleotide primers to be designed to be identical or similar to the polynucleotide sequence that is the target for the amplification. PCR comprises steps of denaturation of template nucleic acid (if double-stranded), annealing of primer to target, and polymerisation. The nucleic acid probed or used as template in the amplification reaction may be genomic DNA, cDNA or RNA. PCR can be used to amplify specific sequences from genomic DNA, specific RNA sequences and cDNA transcribed from mRNA, bacteriophage or plasmid sequences. The GPI-PLD protein nucleic acid sequences provided herein readily allow the skilled person to design PCR primers. References for the general use of

PCR techniques include Mullis et al, Cold Spring Harbor  
Symp. Quant. Biol., 51:263, 1987; Ehrlich (ed), PCR  
Technology, Stockton Press, NY, 1989; Ehrlich et al,  
Science, 252:1643-1650, 1991; "PCR protocols; A Guide to  
5 Methods and Applications", Eds. Innis et al, Academic  
Press, New York, 1990.

Nucleic acid according to the present invention is  
obtainable using one or more oligonucleotide probes or  
10 primers designed to hybridize with one or more fragments  
of the nucleic acid sequence shown in the figures,  
particularly fragments of relatively rare sequence, based  
on codon usage or statistical analysis. A primer  
designed to hybridize with a fragment of the nucleic acid  
15 sequence shown in the above figures may be used in  
conjunction with one or more oligonucleotides designed to  
hybridize to a sequence in a cloning vector within which  
target nucleic acid has been cloned, or in so-called  
"RACE" (rapid amplification of cDNA ends) in which cDNA's  
20 in a library are ligated to an oligonucleotide linker and  
PCR is performed using a primer which hybridizes with a  
GPI-PLD nucleic acid sequence shown in figures and a  
primer which hybridizes to the oligonucleotide linker.

25 Such oligonucleotide probes or primers, as well as the  
full-length sequence (and mutants, alleles, variants and  
derivatives) are also useful in screening a test sample  
containing nucleic acid for the presence of alleles,  
mutants and variants, especially those that lead to the  
30 production of inactive forms of GPI-PLD protein, the  
probes hybridizing with a target sequence from a sample  
obtained from the individual being tested. The  
conditions of the hybridization can be controlled to  
minimise non-specific binding, and preferably stringent  
35 to moderately stringent hybridization conditions are

preferred. The skilled person is readily able to design such probes, label them and devise suitable conditions for the hybridization reactions, assisted by textbooks such as Sambrook et al (1989) and Ausubel et al (1992).

5 Examples of "stringent conditions" are those which: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulphate at 50°C; (2)  
10 employ during hybridisation a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% BSA/0.1% Ficoll/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750mM sodium chloride, 75mM sodium citrate at 42°C; or (3) employ 50% formamide,  
15 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50mg/ml), 0.1% SDS, and 10% dextran sulphate at 42°C, with washes at 42°C in 0.2 x SSC and 50% formamide at  
20 55°C, followed by high stringency wash consisting of 0.1 x SSC containing EDTA at 55°C. These hybridisation conditions may be used in the context of defining nucleic acid sequences which hybridize with GPI-PLD nucleic acid sequences.

#### 25 Uses of GPI-PLD Nucleic Acid

The GPI-PLD nucleic acid sequences can be used in the preparation of cell lines capable of expressing GPI-PLD and included in expression vectors or otherwise  
30 formulated, e.g. for use in gene therapy techniques.

Thus, the present invention provides a cell line for transplantation into a patient, the cell line being transformed with nucleic acid encoding GPI-PLD, and being  
35 capable of expressing and secreting GPI-PLD. In one

embodiment, the cell lines are encapsulated, e.g. in a biocompatible polymer, so that the GPI-PLD produced by the cell line can be secreted into the patient, while preventing rejection by the immune system of the host.

5 Methods for encapsulating cells in biocompatible polymers are described in WO93/16687 and WO96/31199.

As a further alternative, the nucleic acid encoded the GPI-PLD protein could be used in a method of gene  
10 therapy, to treat a patient who is unable to synthesize the active polypeptide or unable to synthesize it at the normal level, thereby providing the effect provided by wild-type GPI-PLD protein and suppressing the occurrence of diabetes in the target cells.

15 Vectors such as viral vectors have been used in the prior art to introduce genes into a wide variety of different target cells. Typically, the vectors are exposed to the target cells so that transfection can take place in a  
20 sufficient proportion of the cells to provide a useful therapeutic or prophylactic effect from the expression of the desired polypeptide. The transfected nucleic acid may be permanently incorporated into the genome of each of the targeted tumour cells, providing long lasting  
25 effect, or alternatively the treatment may have to be repeated periodically.

A variety of vectors, both viral vectors and plasmid vectors, are known in the art, see US Patent No:  
30 5,252,479 and WO93/07282. In particular, a number of viruses have been used as gene transfer vectors, including papovaviruses, such as SV40, vaccinia virus, herpesviruses, including HSV and EBV, and retroviruses. Many gene therapy protocols in the prior art have used  
35 disabled murine retroviruses.

As an alternative to the use of viral vectors other known methods of introducing nucleic acid into cells includes electroporation, calcium phosphate co-precipitation, mechanical techniques such as microinjection, transfer mediated by liposomes and direct DNA uptake and receptor-mediated DNA transfer.

As mentioned above, the aim of gene therapy using nucleic acid encoding the GPI-PLD protein, or an active portion thereof, is to increase the amount of the expression product of the nucleic acid in cells in which the level of the wild-type GPI-PLD protein is absent or present only at reduced levels. Target cells for gene therapy include insulin secreting b-cells or any neuron derived cells. Cell engineering can be used to provide the overexpression or repression of GPI-PLD protein in transfected cell lines which can then be subsequently transplanted to humans. Gene therapy can be employed using a promoter to drive GPI-PLD protein expression in a tissue specific manner (i.e. an insulin promoter linked to GPI-PLD cDNA will overexpress GPI-PLD protein in b-cells and transiently in the brain). If defective function of GPI-PLD protein is involved in neurological disease, GPI-PLD protein can be overexpressed in transformed cell lines for transplantation.

Gene transfer techniques which selectively target the GPI-PLD nucleic acid to target tissues are preferred. Examples of this included receptor-mediated gene transfer, in which the nucleic acid is linked to a protein ligand via polylysine, with the ligand being specific for a receptor present on the surface of the target cells.

#### Diagnostic Methods

Methods for determining the concentration of analytes in biological samples from individuals are well known in the art and can be employed in the context of the present invention to determine the presence or amount of GPI-PLD or a product of GPI-PLD action in a biological sample from a patient. This in turn can allow a physician to determine whether a patient suffers from one of the conditions discussed above and so optimise the treatment of it.

As discussed above, the conditions include diabetes and diabetic complications, liver dysfunction or disorders involving pancreatectomies, and conditions mediated by a product of an infectious organism which is capable of inhibiting GPI-PLD, such as septic shock.

Broadly, the methods divide into those screening for the presence of GPI-PLD protein nucleic acid sequences and those that rely on detecting the presence or absence of the GPI-PLD protein polypeptide or a product of GPI-PLD action (e.g. IPGs or acyl-IPGs). The methods make use of biological samples from individuals that are suspected of contain the nucleic acid sequences or polypeptide.

These diagnostic methods can employ biological samples such as blood, serum, tissue samples or urine. In view of the fact that the activity of GPI-PLD is thought to be due to the level of the enzyme circulating in serum, the use of serum or blood samples is preferred.

The assay methods for determining the amount or concentration of GPI-PLD protein typically either employ binding agents having binding sites capable of specifically binding to GPI-PLD or the product of GPI-PLD action in preference to other molecules or measure a

characteristic biological activity of GPI-PLD. Examples of binding agents include antibodies, receptors and other molecules capable of specifically binding the enzyme. Conveniently, the binding agent(s) are immobilised on  
5 solid support, e.g. at defined locations, to make them easy to manipulate during the assay.

In one format, the methods of diagnosing the conditions relating to GPI-PLD disclosed herein comprises the steps  
10 of:

(a) contacting a biological sample obtained from the patient with a solid support having immobilised thereon a binding agent having binding sites specific for GPI-PLD or a product of GPI-PLD action;

15 (b) contacting the solid support with one or more labelled developing agents capable of binding to unoccupied binding sites, bound GPI-PLD or product, or occupied binding sites; and,

(c) detecting the label of the developing agents  
20 specifically binding in step (b) to obtain a value representative of the amount of GPI-PLD or the product of GPI-PLD action in the sample.

Alternatively or additionally, the method can assess GPI-  
25 PLD levels by measuring one of its biological activities, which are discussed further below.

The products of GPI-PLD action include acyl-IPGs and IPGs, the characteristic activities of which are  
30 discussed above. Antibodies which are capable of binding to IPGs are disclosed in WO98/1116, WO98/11117 and WO99/47565.

The sample is generally contacted with the binding  
35 agent(s) under appropriate conditions so that GPI-PLD

present in the sample can bind to the binding agent(s). The fractional occupancy of the binding sites of the binding agent(s) can then be determined using a developing agent or agents. Typically, the developing agents are labelled (e.g. with radioactive, fluorescent or enzyme labels) so that they can be detected using techniques well known in the art. Thus, radioactive labels can be detected using a scintillation counter or other radiation counting device, fluorescent labels using a laser and confocal microscope, and enzyme labels by the action of an enzyme label on a substrate, typically to produce a colour change. The developing agent(s) can be used in a competitive method in which the developing agent competes with the analyte for occupied binding sites of the binding agent, or non-competitive method, in which the labelled developing agent binds analyte bound by the binding agent or to occupied binding sites. Both methods provide an indication of the number of the binding sites occupied by the analyte, and hence the concentration of the analyte in the sample, e.g. by comparison with standards obtained using samples containing known concentrations of the analyte.

### Experimental

In one embodiment, the present invention is based on the realisation that GPI-PLD is responsible for the production of IPG second messengers following binding of insulin to its receptor. The IPGs then interact with other cellular enzymes instigating some of the metabolic effects of the hormone. In view of this, insulin resistance may be caused by deficiencies in GPI-PLD; it has shown that pancreatic islet cells produce and secrete GPI-PLD, which is transported in blood complexed with apolipoprotein A1, and may therefore represent the major source of circulating enzyme. If this is indeed the case



then the insulin resistance seen in early type I diabetes mellitus (IDDM) may result from decreased circulating GPI-PLD levels. This may have direct therapeutic relevance in that co-infusion of insulin with GPI-PLD may in fact be a far more effective therapy for diabetic patients than insulin.

In a further embodiment, the present invention is based on the realisation that GPI-PLD can be used in the treatment of liver dysfunction, and in particular combination with apolipoprotein A1 to which it is bound in human serum and blood. As GPI-PLD is transported in blood complexed with apolipoprotein A1, liver dysfunction, and especially dysfunction characterised by reduced apolipoprotein A1 levels, can be treated using GPI-PLD.

In a third embodiment, the present invention is based on the observation that in conditions such as septic shock, endotoxin is released from the microorganisms causing sepsis, leading to the clinical symptoms of septic shock such as total organ failure and fatal shock. The endotoxins can be glycolipids released from gram negative bacteria or glycolipids such as LAM released from *Mycobacteria* such as *Tuberculosis*. Without wishing to be bound by any particular theory, these endotoxins are believed to act by inhibiting GPI-PLD.

#### Screening of human liver cDNA library

A human liver cDNA library (Gibco BRL, cat # 10422-012, lot # HF4703) was screened for GPI-PLD, resulting in the isolation of 3 cDNA clones. The nucleic acid sequences of the clones are shown in Figures 4 to 6, with the deduced amino acid sequences shown in Figure 3.

Clone a1 represents the full length cDNA. There are only two differences within the coding region of this sequence when compared to that of the human GPI-PLD pancreatic form described in the GenBank database (accession number L11702). These are a *g* to *a* conversion at positions 88 (L11702), 199 (a1) and a *t* to *g* conversion at positions 797 (L11702), 908(a1). Interestingly this latter conversion creates a unique *HindIII* restriction site in the a1 clone. Both conversions result in amino acid differences, the first changes amino acid 30 from a valine in L11702 to an isoleucine in a1, and the second changes amino acid 266 from an isoleucine in L11702 to a serine in a1. Clone a1 also differs from L11702 in that it contains 5' untranslated region (UTR) and only shares the first 168 bases of the 3' UTR before terminating in a poly-A tail.

Clone b2 lacks exons 23-25 of GPI-PLD, which begins at position 2469 in the a1 nucleotide sequence. However, the sequence from here to the end of b2 (2444-2473) does not contain a stop codon. It is therefore not clear whether b2 represents a cDNA with a different final exon or is the produce of aberrant processing.

Clone d3 shared the 3' coding and 3' UTR sequence of the a1 clone from position 1119 onwards, however the initial 1008 base pairs of coding sequence representing the initial 12 exons, are absent from this clone. Clone d3 contains a methionine initiation codon in frame to the coding sequence at position 202 and a unique 5' UTR. Translation of d3 from this codon would result in a unique sequence of 6 amino acids (1-6). Clone d3 therefore appears to represent a true transcript, in that it contains initiation and stop codons and both 5' and 3' UTRs. The predicted protein product of this transcript

would apparently lack the catalytic domain, which has been localised to the N-terminus of the GPI-PLD enzyme (amino acids 1-375), however the 4 EF hand-like domains would still be present.

5

Huang et al and Tsang et al (1992) reported that two variants or isoenzymes of GPI-PLD exist, the so-called liver and pancreatic forms (accession numbers L11701 and 11702). Other workers have detected L11702 cDNAs in  
10 human breast, eye, spleen, tonsil, and pancreas, as well as in liver. However, we failed to detect the liver form of GPI-PLD in the liver or in any other tissues.

#### Gene mapping and localisation

15 The chromosomal gene isolated in the experiments above is over 100 kb in length. The gene was also isolated on a PAC and mapped by fluorescence-in situ hybridisation (FISH) to 6p22.3 extending into 6p21.3, agreeing with recent radiation hybrid maps as seen on GeneMap'98;  
20 NCBI). The IDDM1 susceptibility gene also maps to 6p21.3, although recent evidence suggests that at least two closely-linked loci for IDDM1 are in the MHC region. The MHC locus itself seems to map to a region adjoining the GPI-PLD locus rather than within the same  
25 microsatellite band, so the significance of the proximity of the GPI-PLD and IDDM1 loci is unclear.

Northern blots of the mRNA species found in liver have shown two presumed splice variants as well as the full-  
30 length transcript. One has a deletion of about 160 amino acids from the mature 817 amino acid protein. The other seems to be a C-terminal deletion, which may therefore be non-functional if other authors are correct in finding that the C-terminus is necessary for enzyme activity.

35

The predominant GPI-PLD species detected after tissue extraction by antibodies (Western blots) has apparent molecular weight of about 47 kD, which agrees with other authors that full-length GPI-PLD is taken up from the plasma and processed to smaller active species.

#### PCR Analysis of GPI-PLD isoforms

PCR was used to compare the expression of putative cDNAs L11701 and L11702 using oligos pairs in cDNA made from human liver mRNA or in genomic DNA. cDNA synthesis reactions from which reverse transcriptase was omitted served as negative controls.

Two regions of the cDNAs were found to have a sufficient number of base differences to enable the synthesis of isoform-specific oligonucleotides. Region 1 contained 6 base pair changes over a total length of 25 nucleotides. From this region two isoform-specific reverse oligos were made:

P2	cagcagaggctgcgcgtcagatatg	(L11702: 2115-2091)
L2	cagcgggtggctgcaggtcggatgtg	(L11701: 2150-2126)

These were matched with forward oligos for gc content from a region approximately 700bp upstream. This region is shown below with differences highlighted in bold and the oligo sequences underlined:

P1	<u>atggttgga</u> ctttaac <b>atggacggc</b> gtgcctgacctggccg
(L11702: 1366-1405)	
L1	atggttgga <b>ctttaacatggatggc</b> gtgcctgac <b>ctggccg</b>
(L11701: 1400-1440)	

Region 2 (1 (L11701; L11702) contained 9 base pair

changes over a total length of 32 nucleotides and was used to make two isoform-specific reverse oligos as before:

- 5 P19 **gtacgtaggggctccaaccagcagcacttggtt**(L11702: 2019-1988)  
L4 **acgtgtcggggctcccaccagcagcacctggg**(L11701: 2054-2023)

These oligos were paired with a single oligo which recognizes both isoforms approximately 300bp upstream  
10 which would also enable PCR from genomic DNA:

U2 **tggttgggagcccgacctggaagaatgccagc**  
(L11702: 1787-1818; L11701: 1822-1853)

15 5mg total human liver RNA (Invitrogen) was reverse transcribed using Superscript II (GibcoBRL) for 90 mins in a total volume of 35ul. Negative controls contained 5mg of RNA but no reverse transcriptase (lanes 2, 4, 6 and 9). 2.5ml of this reaction or 888ng of human genomic  
20 DNA (Promega) was transferred to a 50ml PCR reaction containing 25pmoles of each oligo. After an initial 4 min 94°C denaturing cycle, 30 cycles were performed (25 secs denaturing - 94°C, 30 secs annealing, 30 secs extension - 72°C) and PCR products resolved on a 1%  
25 agarose gel. Annealing temperatures of the oligo pairs were as follows: P1 & P2 - 62°C; L1 & L2 - 66°C; U2 & P19 - 68.3°C; U2 & L4 - 71.5°C).

### Southern Blot

30 A Southern blot of PAC 282J10 DNA and human genomic DNA was hybridised with a cDNA probe containing exons 15-19. The same bands hybridise in both PAC and genomic DNA therefore suggesting that only one copy of the GPI-PLD gene is present in the human genome. This result is in  
35 accord with the finding of only one gene in the mouse.

(LeBoeuf et al, Mammalian Genome 9:710-714, 1998).

4mg of human genomic DNA or 1mg of PAC 282J10 DNA was digested with the restriction enzymes ApaI, EcoRI or NsiI (Promega) at 37°C overnight and run on 1% agarose gel, which was denatured, neutralised and blotted in 20XSSC overnight. DNA was UV crosslinked onto the blot and then hybridised with <sup>32</sup>P-labelled P1/P2 PCR product. The blot was then washed with decreasing SSC concentrations, the final wash being 0.2XSSC, 0.1%SDS for 20 mins at 65°C. Autoradiographs were exposed at -80°C for 1h (282J10) or 3 days (genomic).

#### **GPI-PLD gene structure**

The structure of the human GPI-PLD gene has been determined. It comprises 25 exons and extends over more than 100 kb of chromosome 6p22.3 into 6p21.3. We have used Southern blot analysis to determine that only one GPI-PLD gene exists in the human genome.

Using PCR analysis as described above, we have been unable to prove the existence of the so-called liver form of GPI-PLD (GenBank accession number L11701), whereas the so called pancreas form (L11702) is the form we have detected in human liver. These data show that the two forms do not exist alongside each other in the human liver, however it is still possible that L11701 represents a polymorphic variant not seen in the subjects from whom our liver RNA was obtained.

#### **GPI-PLD gene expression**

Using PCR we have compared the expression of GPI-PLD in cDNA libraries made from human tissues. GPI-PLD appears most abundant in the liver followed by the lung. A very low level of expression was seen in kidney and heart and

skeletal muscle, however we were unable to detect expression in pancreas, brain or placenta.

Recombinant GPI-PLD has been purified from stable CHO cell lines transfected with the full-length human GPI-PLD cDNA clone a1 isolated previously from a human liver cDNA library. Recombinant GPI-PLD cleaves the GPI substrate mfVSG, and like its counterpart purified from serum, this action is inhibited by prior incubation with the transition metal ion chelator 1,10-phenanthroline.

We have identified at least two systems which do not appear to express the GPI-PLD gene, namely the human placenta and the rat basophil-like cell line RBL2H3.

However in both cases abundant GPI-PLD protein and enzyme activity is detectable, thus confirming our prediction that in tissues which do not express the gene, protein is still expressed and is presumably uptaken from the vast reserves found in serum. Experiments using the mouse skeletal muscle cell line C2C12 indicate that over 70% of the GPI-PLD activity present within the cells is derived from serum.

#### **GPI-PLD obtained from serum by cells is required for second messenger signalling**

The principle goal of these experiments was to determine the role of glycosylphosphatidylinositol phospholipase D (GPI-PLD) in a type one hypersensitivity reaction. This reaction involved the cross-linking of IgE receptors on the mast cell surface, leading to the release of allergic mediators.

Such an allergic reaction has been experimentally reproduced in our laboratory, using a rat basophilic leukaemia cell line, RBL-2H3. These cells naturally have

unoccupied IgE receptors (FcεR1, or high-affinity receptors), allowing them to be passively sensitised with an IgE isotype of choice.

- 5 RBL-2H3 cell culture was maintained in Eagles minimum essential medium, containing 10% Foetal Bovine Serum (FBS) (heat activated), 100 U/ml Penicillin, 100 mg/ml Streptomycin and 2 mM L-glutamine.
- 10 Previous research indicates that RBL-2H3 cells derive their GPI-PLD from the culture serum (data not shown). Therefore, it follows that inactivation of this external source of GPI-PLD would deprive the cells of any further enzyme.
- 15 Inactivation of GPI-PLD activity in foetal bovine serum was achieved according to the method of Kung et al (Biochimica et Biophysica Acta, 1357:329-338, 1997). Briefly, FCS was adjusted to pH 11 using concentrated
- 20 hydrochloric acid, and incubated for 1 hour at 37°C using. After this time, the pH was adjusted to 7.4, and GPI-PLD activity was determined using an enzymatic assay (Davitz et al, J. Biol. Chem., 264:13760-13764, 1989). Results indicated that this alkaline incubation severely
- 25 depleted GPI-PLD activity (data not shown).

To determine the effect of culture of RBL-2H3 cells in GPI-PLD inactive serum, the supplemented MEM was replaced with MEM in which the FBS had been inactivated. Although

30 the cell appearance was not dramatically altered by the altered culture conditions, determination of GPI-PLD activity showed a dramatic reduction in activity.

**GPI-PLD activity in cells cultured with GPI-PLD**

35 **active/inactive FBS:**



Active = 0.66 units GPI-PLD activity/mg of protein.

Inactive = 0.11 units GPI-PLD activity/mg of protein.

5 The effect of a reduced GPI-PLD activity on the cell's ability to respond to IgE cross-linking was determined as follows:

10 RBL-2H3 cells were grown to confluence, after which time the adherent cells were removed from the culture flask using a cell scraper. The cell density was determined, using a haemocytometer, and adjusted to  $2 \times 10^5$  per ml. The cells were seeded at 1 ml per well in a 24 well culture plate and cultured for overnight at 37°C in a humidified 5% CO<sub>2</sub> incubator.

15 The overnight culture media was aspirated and replaced with fresh media containing Rat IgE anti-DNP 3mg/ml. After a 2 hour incubation period, the media was aspirated, and the cells were washed twice, with HEPES  
20 Buffered Saline. Cross-linking was achieved by the addition of 200 ml of DNP-Albumin at 100 ng/ml, and incubation for 2 hours. Mediator release was determined using a colorimetric assay to detect the presence of b-hexosaminidase and compared with the total cell b-hexosaminidase content (as determined by incubation with  
25 200 ml 5% Triton X-100 detergent). (Yasuda et al, Int. Immunol., 7:251-258, 1995). As shown in the table below, the responsiveness to cross-linking was significantly reduced in those cells that were cultured in GPI-PLD  
30 inactive media.

**Percentage release in IgE linking activity assay  
(compared with total):**

Active GPI-PLD culture = 48.79%

Inactive GPI-PLD culture = 5.07%

#### Phosphorylation of GPI-PLD

The phosphorylation state of the GPI-PLD enzymes was  
5 determined using MALDI-TOF mass spectrometry as described  
by Yip & Hutchins (1992). Spectrums of tryptic digests  
of the proteins can be compared before and after  
treatment with calf intestinal alkaline phosphatase. The  
specific kinases responsible for phosphorylation of GPI-  
10 PLD can then be determined by incubation of the GPI-PLD  
tryptic fragments with ATP in the presence of various  
kinases. Motif analysis of the amino acid sequence of  
human GPI-PLD using the HGMP "motif" package has revealed  
the presence of numerous potential phosphorylation sites  
15 for the enzymes CAMP-dependent protein kinase A, protein  
kinase C and protein kinase ck2 (formerly known as casein  
kinase II). Of these sites we have found that the site  
at amino acids 689-692 is a key site which when  
phosphorylated, e.g. by PKA, inhibits GPI-PLD biological  
20 activity.

These enzymes may therefore be involved in the  
activation/inactivation of GPI-PLD. Intriguingly the  
activity of protein kinase ck2 has been shown to be  
25 modulated by IPGs (Alemany et al, 1990) and there is also  
indirect evidence suggesting that IPGs may act through  
protein kinase C, thus suggesting the possibility of  
feedback loops regulating the production of IPGs.

#### Discussion

30 GPI-PLD is a metalloenzyme with 5 and 10 atoms per  
molecule of calcium and zinc, respectively. It  
circulates in a complex with apolipoprotein A1. GPI-PLD  
is produced in the pancreas by both a and b-cells in the  
35 islets of Langerhans. It is also produced by a mouse

insulinoma cell line (bTC3), with GPI-PLD and insulin generally colocalised intracellularly. The enzyme was shown to be secreted in response to insulin secretagogues. Both isoenzymes of GPI-PLD also seem to be present in liver; a major part of the activity could be washed away from the tissue by extraction with detergent-free buffer (thus, likely to be the plasma enzyme). There is some suggestions that the liver, as well as the pancreas, may contribute to the serum pool of GPI-PLD as patients with liver disease have lower levels of active enzyme, which is correlated with the reduced albumin levels.

It has been shown that streptozotcin-induced diabetes mellitus in the rat reduced the basal content of insulin-sensitive IPG in isolated hepatocytes by about 60%. The authors conclude that insulin resistance in these rats is related to the impairment of IPG metabolism. It has also been shown that the mRNA for a GPI-PLD-like gene was over expressed in genetically obese (ob/ob) mice in comparison to lean litter mates. In the context of the invention described herein, this latter finding suggests that GPI-PLD levels are responsive to the obese/diabetic genotype.

References:

The references mentioned herein are all incorporated by reference in their entirety.

- 5 Huang et al, US Patent No: 5,418,147.
- Tsang et al, FASEB J. (supp), 6:A1922, 1992.
- Scallon et al, Science, 252:446-448, 1991.
- 10 Hoener et al, Eur. J. Biochem., 206:747-757, 1992.
- Li et al, J. Biol. Chem., 269:28963-28971, 1994.
- 15 Heller et al, Eur. J. Biochem., 224:823-833, 1994.
- Jones et al, Biochem. Biophys. Res. Comm., 233:432-437, 1997.
- 20 Rademacher et al, Brazilian J. Med. Biol. Res., 27:327-341, 1994.
- Lin et al, J. Cell Biol., 115:220a, 1991
- 25 Thompson et al, Nucleic Acid Research, 22:4673-4680, 1994, with algorithm from Higgins et al, CABIOS, 8(2):189-191, 1992.
- Alemaný et al, Nature, 330:77-79, 1987.
- 30 Caro et al, Biochem. Molec. Med., 61:214-228, 1997.
- Deeg & Verchere, Endocrinology, 136:819-826, 1997.
- 35 LeBoeuf et al, Mammalian Genome 9:710-714, 1998.

Claims:

1. Glycosylphosphatidyl inositol specific phospholipase D (GPI-PLD) for use in a method of medical treatment.

5 2. The GPI-PLD of claim 1, wherein the GPI-PLD is simultaneously or sequentially administered with apolipoprotein A1.

10 3. A nucleic acid molecule encoding GPI-PLD for use in a method of medical treatment.

15 4. Use of GPI-PLD for the preparation of a medicament for the treatment of conditions that respond to GPI-PLD or which are characterised by reduced levels of GPI-PLD as compared to a normal patient.

20 5. Use of the presence or amount of GPI-PLD in a sample from a patient in the diagnosis of a condition that responds to GPI-PLD or which is characterised by reduced levels of GPI-PLD as compared to a normal patient.

25 6. The use of claim 5, wherein the presence or amount of GPI-PLD is determined by measuring one of its biological activities.

30 7. Use of glycosylphosphatidyl inositol specific phospholipase D (GPI-PLD) for the preparation of a medicament for the treatment of diabetes or diabetic complications.

8. The use of claim 7, wherein the diabetes is an insulin dependent form of diabetes.

35 9. The use of claim 7 or claim 8, wherein the diabetes is Type I or Type II diabetes.

10. -The use of claim 7, wherein the complications of diabetes are due to insulin resistance.

11. The use of any one of claims 7 to 10, wherein the medicament further comprises insulin, a glucose sparing or insulin enhancing drug, an  $\alpha$ -glucosidase inhibitor or drug to treat insulin sensitivity, a P and/or A-type inositolphosphoglycan (IPG) and/or an IPG antagonist.

12. Use of a nucleic acid molecule encoding GPI-PLD, in the preparation of a medicament for the treatment of diabetes or diabetic complications.

13. Use of glycosylphosphatidyl inositol specific phospholipase D (GPI-PLD) for the preparation of a medicament for the treatment of liver dysfunction or disorders involving pancreatectomies.

14. The use of claim 13, wherein the medicament further comprises apolipoprotein A1.

15. Use of a nucleic acid molecule encoding GPI-PLD in the preparation of a medicament for the treatment of liver dysfunction.

16. The use of any one of the preceding claims, wherein the liver dysfunction is characterised by reduced levels of apolipoprotein A1 and/or GPI PLD and/or apolipoprotein A1/GPI-PLD complex as compared to a normal patient.

17. Use of glycosylphosphatidyl inositol specific phospholipase D (GPI-PLD) for the preparation of a medicament for the treatment of a condition mediated by a product of an infectious organism which is capable of inhibiting GPI-PLD.

18. The use of claim 17, wherein the condition is mediated by an endotoxin.

19. The use of claim 18, wherein the endotoxin is a glycolipid from a *Mycobacterium* or gram negative bacteria.

20. The use of any one of claims 17 to 19, wherein the condition is septic shock.

21. Use of a nucleic acid molecule encoding glycosylphosphatidyl inositol specific phospholipase D (GPI-PLD) for the preparation of a medicament for the treatment of a condition mediated by a product of an infectious organism which is capable of inhibiting GPI-PLD.

22. A cell line transformed with nucleic acid encoding GPI-PLD, and capable of expressing and secreting GPI-PLD, for use in a method of medical treatment.

23. The cell line of claim 22, wherein the cell line is capable of producing apolipoprotein A1.

24. The use of the cell line of claim 22 or claim 23, in the preparation of a medicament for treatment of diabetes or diabetic complications, liver dysfunction or disorders involving pancreatectomies, or a condition mediated by a product of an infectious organism which is capable of inhibiting GPI-PLD, such as septic shock.

25. A pharmaceutical composition comprising a nucleic acid molecule encoding a GPI-PLD protein.

26. A pharmaceutical composition comprising a GPI-PLD

protein.

27. The composition of claim 22, further comprising apolipoprotein A1.

28. A method of diagnosing a condition selected from diabetes or diabetic complications, liver dysfunction or disorders involving pancreatectomies, a condition mediated by a product of an infectious organism which is capable of inhibiting GPI-PLD, the method comprising:

determining the amount of GPI-PLD or a product of GPI-PLD action in a sample from a patient and correlating the amount to standards to determine whether the patient has or is at risk from said condition.

29. The method of claim 28, which comprises the steps of:

(a) contacting a biological sample obtained from the patient with a solid support having immobilised thereon a binding agent having binding sites specific for GPI-PLD or the product of GPI-PLD action;

(b) contacting the solid support with one or more labelled developing agents capable of binding to unoccupied binding sites, bound GPI-PLD or product, or occupied binding sites; and,

(c) detecting the label of the developing agents specifically binding in step (b) to obtain a value representative of the amount of GPI-PLD or the product of GPI-PLD action in the sample.

30. The method of claim 28, wherein the amount of GPI-PLD in the sample is determined by measuring GPI-PLD activity.

31. The method of claim 28 or claim 29, wherein the



product of GPI-PLD action are acyl-IPGs or IPGs.

32. An isolated or substantially isolated GPI-PLD protein with an amino acid sequence as shown in Figure 3.

33. An isolated nucleic acid sequence encoding a GPI-PLD as shown in any one of Figures 4 to 6.

34. An isolated nucleic acid sequence encoding a GPI-PLD, with greater than 90% identity with any one of the nucleic acid sequences shown in Figures 4 to 6.

35. An expression vector comprising nucleic acid sequence encoding a GPI-PLD protein as shown in any one of Figures 4 to 6.

36. A variant GPI-PLD polypeptides differing in amino acid sequence in the region corresponding to amino acid residues 689-692 inclusive (RRFS) of human wild-type GPI-PLD.

37. The variant of claim 36 which comprises a substitution in the region corresponding to amino acids 689-692 of mature human wild-type GPI-PLD.

38. The variant of claim 37, wherein the substitution changes the serine residue at position 692 to an amino acid other than serine or threonine.

39. The variant of any one of claims 36 to 38 for use in a method of medical treatment.

40. An isolated nucleic acid molecule encoding the variant GPI-PLD polypeptide of any one of claims 36 to 38.

41. The nucleic acid of any one of claims 36 to 38 for use in a method of medical treatment.

42. An expression vector comprising the nucleic acid molecule of claim 41, operably linked to control sequences to direct its expression.

43. A host cell transformed with the nucleic acid molecule of claim 41 encoding a GPI-PLD variant polypeptide.

44. A method of producing a variant GPI-PLD polypeptides which comprises culturing the host cells of claim 43 so that the variant GPI-PLD polypeptide is expressed and isolating the polypeptide thus produced.

45. The method of claim 44 which comprises the further step of then formulating the variant GPI-PLD polypeptide in a composition.

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N 9/00</b>	<b>A2</b>	(11) International Publication Number: <b>WO 00/39285</b> (43) International Publication Date: <b>6 July 2000 (06.07.00)</b>									
<p>(21) International Application Number: <b>PCT/GB99/04399</b></p> <p>(22) International Filing Date: <b>23 December 1999 (23.12.99)</b></p> <p>(30) Priority Data:</p> <table border="0"> <tr> <td>9828712.1</td> <td>24 December 1998 (24.12.98)</td> <td>GB</td> </tr> <tr> <td>9828715.4</td> <td>24 December 1998 (24.12.98)</td> <td>GB</td> </tr> <tr> <td>9828713.9</td> <td>24 December 1998 (24.12.98)</td> <td>GB</td> </tr> </table> <p>(71) Applicant (for all designated States except US): <b>UNIVERSITY COLLEGE LONDON [GB/GB]; Gower Street, London WC1E 6BT (GB).</b></p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): <b>SCHOFIELD, Julian [GB/GB]; 59 Moorgreen House, Wynyatt Street, London EC1V 7JA (GB). RADEMACHER, Thomas, William [US/GB]; Foxcombe, The Ridgeway, Boars Hill, Oxford OX1 5EY (GB).</b></p> <p>(74) Agents: <b>KIDDLE, Simon, J. et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).</b></p>		9828712.1	24 December 1998 (24.12.98)	GB	9828715.4	24 December 1998 (24.12.98)	GB	9828713.9	24 December 1998 (24.12.98)	GB	<p>(81) Designated States: <b>AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b></p> <p><b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i></p>
9828712.1	24 December 1998 (24.12.98)	GB									
9828715.4	24 December 1998 (24.12.98)	GB									
9828713.9	24 December 1998 (24.12.98)	GB									
<p>(54) Title: <b>GLYCOSYL PHOSPHATIDY LINOSITOL SPECIFIC PHOSPHOLIPASE D PROTEINS AND USES THEREOF</b></p>											
<p>(57) Abstract</p> <p>Glycosyl phosphatidy linositol specific phospholipase D (GPI-PLD) proteins and their medical uses are disclosed, in particular in the treatment and diagnosis of diabetes and complications of diabetes such as insulin resistance, liver dysfunction, disorders involving pancreatetectomies and conditions mediated by a product of an infectious organism which is capable of inhibiting GPI-PLD, such as septic shock. The present invention further relates to variant GPI-PLD polypeptides modified at the phosphorylation site at amino acids 689-692 of the mature human wild-type protein.</p>											

1/20

**Figure 1**

Top: protein produced from cDNA clone A1  
Mid: protein produced from Roche patent bovine liver sequence  
Bot: protein produced from Roche patent human liver sequence

MSAFRLWPGLLIMLG-SLCHRGSPCGLSTHIEIGHRALEFLQLHNGRVNYRELLLEHQDA  
MSAFRFWSGLLMLLG-FLCPRSSPCGISTHIEIGHRALEFLHLQDGSINYKELLRRHQDA  
MSAFRLWPGLLMIVMASLCHRGSSCGLSTHIEIGHRALEFLHLHNGHVNYKELLLEHQDA

YQAGIVFPDCFYPSICKGGKFHDVSESTHWTPLNASVHYIRENYPLPWEKDTEKLVAFL  
YQAGSVFPDSFYPSICERGFHDVSESTHWTPLNASVHYIRKNYPLPWDEDTEKLVAFL  
YQAGTVFPDCFYPSLCKGGKFHDVSESTHWTPLNASVHYIRENYPLPWEKDTEKLVAFL

FGITSHMAADVSWHSLGLEQGFRLTMGAIDFHGSYSEAHSAAGDFGGDVLSQFEFNFNYLA  
FGITSHMVADVWNHSLGIENGFLRTMAAIDFHNSYPEAHPAGDFGGDVLSQFEFKFNLYS  
FGITSHMVADVSWHSLGIEQGFRLTMGAIDFHGSYSEAHSAAGDFGGDVLSQFEFNFNYLA

RRWYVPVKDLLGIYEKLYGRKVITENVIVDCSHIQFLEMYGEMLA VSKLYPTYSTKSPFL  
RHWYVPAEDLLGIYRELYGRIVITKKAIVDCSYLQFLEMYAEMLAISKLYPTYSVKSPFL  
RRWYVPVKDLLGIYEKLYGREVITENVIVDCSHIQFLEMYGEMLA VSKLYPSYSTKSPFL

VEQFQEYFLGGLDDMAFWSTNIYHLTSFMLENGTSDCNLPENPENPLFIACGGQQNHTQG  
VEQFQEYFLGGLDDMAFWSTNIYHLTSTMLKNGTSN CNLPENP ---LFITCGGQQNNTHG  
VEQFQEYFLGGLDDMAFWSTNIYHLTSFMLENGTSDCSLFENPENPLFIACGGQQNHTQG

SKMQKNDFHRNLTSSLTESVDRNIN YTERGVFFSVNSWTPDMSFSFIYKALERNIRTMFIG  
SKVQKNGFHKNVTAALTKNIGKHINYTKRGVFFSVDSWTMDFLSFMYKSLERSIREMFIG  
SKMQKNDFHRNLTSSLTENIDRNIN YTERGVFFSVNSWTPDMSFSFIYKALERNVRTMFIG

GSQLSQKHVSSPLASYFLSFYARLGWAMTSADLNQDGHGDLVVGAPGYSRPGHIHIGRV  
SSQP-LTHVSSPAASYLSFPYTRLGWAMTSADLNQDGYGDLVVGAPGYSHPGRIHVGRV  
GSQLSQKHISSPLASYFLSFYARLGWAMTSADLNQDGYGDLVVGAPGYSRPGRIHIGRV

YLIYGNDLGLPPVDLDLDKEAHRILEGFQPSGRFGSALAVLDFNVDGVPDLAVGAPSVGS  
YLIYGNDLG-PRIDLDDKEAHGILEGFQPSGRFGSAVAVLDFNVDGVPDLAVGAPSVGS  
YLIYGNELGLPPVDLDLDKEAHGILEGFQPSGRFGSALAMLDNMDGVPDLAVGAPSVGS

EQLTYKGAVVYVFGSKQGGMSSSPNITISCQDIYCNLGWTLAADVNGDSEPD-LVIGSP  
EKLTYTGA VVYVFGSKQQLSSSPNVTISCQDTYCNLGWTLAADVGDSEPD L FVIGSP  
EQLTYKGAVVYVFGSKQGRMSSSPNITISCQDIYCNLGWTLAADVNGDSEPD-LVIGSP

FAPGGGKQKGIVAAFYSGPSLSDKEKLNVEAANWTVRGEEDFSWFGYSLHGVTVDNRTLL  
FAFGGKQKGIVAAFYSGSSYSREKLNVEAANWVMVKEEDFAWLGYSLHGVNVNRTLL  
FAPGGGKQKGIVAAFYSGRSLSNKEKLNVEAANWTVRGEEDFAWFGYSLHGVTVDNRTLL

LVGSPTWKNASRLGHLLHIRDEKKS LGRVYGYFPPNGQSWFTISGDKAMGKLGTSLSSGH  
LAGSPTWKDTSSQGH LFRTRDEKQSPGRVYGYFPPICQSWFTISGDKAMGKLGTSLSSGH  
LVGSPTWKNASRLGRLLHIRDEKKS LGRVYGYFPPNSQSWFTIVGDKAMGKLGTSLSSGH

2/20

**Figure 1 continued**

VLNMGTLKQVLLVGAPTYDDVSKVAFLTIVTLHQGGATRMALISDAQPIILLSTFSGDRRF  
VIVNGTRTQVLLVGAPTQDVVSKS-FLTMTLHQGGSTRMYELTPDSQPSILLSTFSGNRRF  
VLNMGTLTQVLLVGAPTRDDVSKMAFLTMTLHQGGATRMALTSDLQPILLSTFSGDRRF

SRFGGVLHLSDDLDDGLDEIIAAPLRIADVTSGLIGGEDGRVYVYNGKETTLDGMTGKC  
SRFGGVLHLSDDLNDGLDEIIAAPLRITDATAGLMGEEDGRVYVFNGKQITVGDVTGKC  
SRFGGVLHLSDDLDDGVDEIIAAPLRIADVTSGLIGGEDGRVYVYNGKETTLDGMTGKC

KSWITPCPEEKAQYVLISPEASSRFGSSLITVRSKAKNQVVIAAGRSSLGARLSGALHVV  
KSWVTPCPEEKAQYVLISPEAGSRFGSSVITVRSKEKNQVIIAAGRSSLGARLSGVLHIY  
KSWMTPCPEEKAQYVLISPEASSRFGSSLITVRSKAKNQVVIAAGRSSLGARLSGALHVV

SLGSD

RLGQD

SLGSD

3/20

## Figure 2

Top: pancreatic-form cDNA sequence from GenBank database  
mid: our sequence cloned from human liver cDNA library  
bot: Roche patent pancreatic-form partial cDNA sequence

```
-----
1   GTGACCTGCTTAGAGAGAAGCGGTGGGTCTGCACCTGGATTTTGGAGTCCCAGTGCTGCT   60
-----

1   -----ATGTCTGCT   9
61  GCAGCTCTGAGCATTCCCACGTCACCAGAGAAGCCGGTGGGCAATGAGAGCATGTCTGCT   120
-----

10  TTCAGGTTGTGGCCTGGCCTGCTGATCATGTTGGGTTCTCTCTGCCATAGAGGTTACCG   69
121 TTCAGGTTGTGGCCTGGCCTGCTGATCATGTTGGGTTCTCTCTGCCATAGAGGTTACCG   180
-----

70  TGTGGCCTTTCAACACACGTAGAAATAGGACACAGAGCTCTGGAGTTTCTTCAGCTTCAC   129
181 TGTGGCCTTTCAACACACATAGAAATAGGACACAGAGCTCTGGAGTTTCTTCAGCTTCAC   240
-----

130 AATGGGCGTGTTAACTACAGAGAGCTGTTACTAGAACACCAGGATGCGTATCAGGCTGGA   189
241 AATGGGCGTGTTAACTACAGAGAGCTGTTACTAGAACACCAGGATGCGTATCAGGCTGGA   300
-----

190 ATCGTGTTTCCTGATTGTTTTTACCCTAGCATCTGCAAAGGAGGAAAATTCCATGATGTG   249
301 ATCGTGTTTCCTGATTGTTTTTACCCTAGCATCTGCAAAGGAGGAAAATTCCATGATGTG   360
-----

250 TCTGAGAGCACTCACTGGACTCCGTTTCTTAATGCAAGCGTTCATTATATCCGAGAGAAC   309
361 TCTGAGAGCACTCACTGGACTCCGTTTCTTAATGCAAGCGTTCATTATATCCGAGAGAAC   420
-----

310 TATCCCCCTTCCCTGGGAGAAGGACACAGAGAACTGGTAGCTTTCTTGTTTGAATTACT   369
421 TATCCCCCTTCCCTGGGAGAAGGACACAGAGAACTGGTAGCTTTCTTGTTTGAATTACT   480
-----

370 TCTCACATGGCGGCAGATGTCAGCTGGCATAGTCTGGGCCTTGAACAAGGATTCCTTAGG   429
481 TCTCACATGGCGGCAGATGTCAGCTGGCATAGTCTGGGCCTTGAACAAGGATTCCTTAGG   540
-----

430 ACCATGGGAGCTATTGATTTTCACGGCTCCTATTTCAGAGGCTCATTTCGGCTGGTGATTTT   489
541 ACCATGGGAGCTATTGATTTTCACGGCTCCTATTTCAGAGGCTCATTTCGGCTGGTGATTTT   600
-----

490 GGAGGAGATGTGTTGAGCCAGTTTGAATTTAATTTTAATTACCTTGCACGACGCTGGTAT   549
601 GGAGGAGATGTGTTGAGCCAGTTTGAATTTAATTTTAATTACCTTGCACGACGCTGGTAT   660
-----

550 GTGCCAGTCAAAGATCTACTGGGAATTTATGAGAACTGTATGGTCGAAAAGTCATCACC   609
661 GTGCCAGTCAAAGATCTACTGGGAATTTATGAGAACTGTATGGTCGAAAAGTCATCACC   720
-----
```

4/20

## Figure 2 continued

610 GAAAATGTAATCGTTGATTGTTACATATCCAGTTCTTAGAAATGTATGGTGAGATGCTA 669  
721 GAAAATGTAATCGTTGATTGTTACATATCCAGTTCTTAGAAATGTATGGTGAGATGCTA 780  
-----  
670 GCTGTTTCCAAGTTATATCCCACTTACTCTACAAAGTCCCCGTTTTTGGTGGAACAATTC 729  
781 GCTGTTTCCAAGTTATATCCCACTTACTCTACAAAGTCCCCGTTTTTGGTGGAACAATTC 840  
-----  
730 CAAGAGTATTTTCTTGGAGGACTGGATGATATGGCATTGTTGGTCCACTAATATTTACCAT 789  
841 CAAGAGTATTTTCTTGGAGGACTGGATGATATGGCATTGTTGGTCCACTAATATTTACCAT 900  
-----  
790 CTAACAATCTTCATGTTGGAGAATGGGACCAGTGACTGCAACCTGCCTGAGAACCCTCTG 849  
901 CTAACAAGCTTCATGTTGGAGAATGGGACCAGTGACTGCAACCTGCCTGAGAACCCTCTG 960  
-----  
850 TTCATTGCATGTGGCGGCCAGCAAAACCACACCCAGGGCTCAAAAATGCAGAAAAATGAT 909  
961 TTCATTGCATGTGGCGGCCAGCAAAACCACACCCAGGGCTCAAAAATGCAGAAAAATGAT 1020  
-----  
910 TTTCACAGAAATTTGACTACATCCCTAACTGAAAGTGTTGACAGGAATATAAACTATACT 969  
1021 TTTCACAGAAATTTGACTACATCCCTAACTGAAAGTGTTGACAGGAATATAAACTATACT 1080  
-----  
970 GAAAGAGGAGTGTTCTTTAGTGTAATTCCTGGACCCCGGATTCCATGTCCTTTATCTAC 1029  
1081 GAAAGAGGAGTGTTCTTTAGTGTAATTCCTGGACCCCGGATTCCATGTCCTTTATCTAC 1140  
-----  
1030 AAGGCTTTGGAAAGGAACATAAGGACAATGTTTCATAGGTGGCTCTCAGTTGTACAAAAAG 1089  
1141 AAGGCTTTGGAAAGGAACATAAGGACAATGTTTCATAGGTGGCTCTCAGTTGTACAAAAAG 1200  
-----  
1090 CACGTCTCCAGCCCCCTTAGCATCTTACTTCTTGTCATTTCTTATGCGAGGCTTGGCTGG 1149  
1201 CACGTCTCCAGCCCCCTTAGCATCTTACTTCTTGTCATTTCTTATGCGAGGCTTGGCTGG 1260  
-----  
1150 GCAATGACCTCAGCTGACCTCAACCAGGATGGGCACGGTGACCTCGTGGTGGGCGCACCA 1209  
1261 GCAATGACCTCAGCTGACCTCAACCAGGATGGGCACGGTGACCTCGTGGTGGGCGCACCA 1320  
-----  
1210 GGCTACAGCCGCCCCGGCCACATCCACATCGGGCGCGTGACCTCATCTACGGCAATGAC 1269  
1321 GGCTACAGCCGCCCCGGCCACATCCACATCGGGCGCGTGACCTCATCTACGGCAATGAC 1380  
-----  
1270 CTGGGCCTGCCACCTGTTGACCTGGACCTGGACAAGGAGGCCACAGGATCCTTGAAGGC 1329  
1381 CTGGGCCTGCCACCTGTTGACCTGGACCTGGACAAGGAGGCCACAGGATCCTTGAAGGC 1440  
-----  
1330 TTCCAGCCCTCAGGTCGGTTTGGCTCGGCCTTGGCTGTGTTGGACTTTAACGTGGACGGC 1389  
1441 TTCCAGCCCTCAGGTCGGTTTGGCTCGGCCTTGGCTGTGTTGGACTTTAACGTGGACGGC 1500  
-----  
1390 GTGCCTGACCTGGCCGTGGGAGCTCCCTCGGTGGGCTCCGAGCAGCTCACCTACAAAGGT 1449  
1501 GTGCCTGACCTGGCCGTGGGAGCTCCCTCGGTGGGCTCCGAGCAGCTCACCTACAAAGGT 1560  
-----

5/20

## Figure 2 continued

1450 GCCGTGTATGTCTACTTTGGTTCCAAACAAGGAGGAATGTCTTCTTCCCCTAACATCACC 1509  
1561 GCCGTGTATGTCTACTTTGGTTCCAAACAAGGAGGAATGTCTTCTTCCCCTAACATCACC 1620  
-----  
1510 ATTTCTTGCCAGGACATCTACTGTAACCTGGGCTGGACTCTCTTGGCTGCAGATGTGAAT 1569  
1621 ATTTCTTGCCAGGACATCTACTGTAACCTGGGCTGGACTCTCTTGGCTGCAGATGTGAAT 1680  
-----  
1570 GGAGACAGTGAACCCGATCTGGTCATCGGCTCCCCTTTTGCACCAGGTGGAGGGAAGCAG 1629  
1681 GGAGACAGTGAACCCGATCTGGTCATCGGCTCCCCTTTTGCACCAGGTGGAGGGAAGCAG 1740  
-----  
1630 AAGGGAATTGTGGCTGCGTTTTATTCTGGCCCCAGCCTGAGCGACAAAGAAAACTGAAC 1689  
1741 AAGGGAATTGTGGCTGCGTTTTATTCTGGCCCCAGCCTGAGCGACAAAGAAAACTGAAC 1800  
1 -----CTGGCCCCAGCCTGAGCGACAAAGAAAACTGAAC 35  
1690 GTGGAGGCAGCCAACTGGACGGTGAGAGGCGAGGAAGACTTCTCCTGGTTTGGATATTCC 1749  
1801 GTGGAGGCAGCCAACTGGACGGTGAGAGGCGAGGAAGACTTCTCCTGGTTTGGATATTCC 1860  
36 GTGGAGGCAGCCAACTGGACGGTGAGAGGCGAGGAAGACTTCTCCTGGTTTGGATATTCC 95  
1750 CTTACGGTGTCACCTGTGGACAACAGAACCTTGCTGTTGGTTGGGAGCCCGACCTGGAAG 1809  
1861 CTTACGGTGTCACCTGTGGACAACAGAACCTTGCTGTTGGTTGGGAGCCCGACCTGGAAG 1920  
96 CTTACGGTGTCACCTGTGGACAACAGAACCTTGCTGTTGGTTGGGAGCCCGACCTGGAAG 155  
1810 AATGCCAGCAGGCTGGGCCATTTGTTACACATCCGAGATGAGAAAAAGAGCCTTGGGAGG 1869  
1921 AATGCCAGCAGGCTGGGCCATTTGTTACACATCCGAGATGAGAAAAAGAGCCTTGGGAGG 1980  
156 AATGCCAGCAGGCTGGGCCATTTGTTACACATCCGAGATGAGAAAAAGAGCCTTGGGAGG 215  
1870 GTGTATGGCTACTTCCCACCAAACGGCCAAAGCTGGTTTACCATTTCTGGAGACAAGGCA 1929  
1981 GTGTATGGCTACTTCCCACCAAACGGCCAAAGCTGGTTTACCATTTCTGGAGACAAGGCA 2040  
216 GTGTATGGCTACTTCC-ACCAAACGGCCAAAGCTGGTTTACCATTTCTGGAGACAAGGCA 275  
1930 ATGGGGAAACTGGGTACTTCCCTTTCCAGTGGCCACGTAAGTGAATGGGACTCTGAAA 1989  
2041 ATGGGGAAACTGGGTACTTCCCTTTCCAGTGGCCACGTAAGTGAATGGGACTCTGAAA 2100  
276 ATGGGGAAACTGGGTACTTCCCTTTCCAGTGGTCACGTAAGTGAATGGGACTCTGAAA 335  
1990 CAAGTGCTGCTGGTTGGAGCCCCTACGTACGATGACGTGTCTAAGGTGGCATTCTGACC 2049  
2101 CAAGTGCTGCTGGTTGGAGCCCCTACGTACGATGACGTGTCTAAGGTGGCATTCTGACC 2160  
336 CAAGTGCTGCTGGTTGGAGCCCCTACGTACGATGACGTGTCTAAGGTGGCATTCTGACC 395  
2050 GTGACCCTACACCAAGGCGGAGCCACTCGCATGTACGCACTCATATCTGACGCGCAGCCT 2109  
2161 GTGACCCTACACCAAGGCGGAGCCACTCGCATGTACGCACTCATATCTGACGCGCAGCCT 2220  
396 GTGACCCTACACCAAGGCGGAGCCACTCGCGTGTACGCACTCATATCTGACGCGCAGCCT 455  
2110 CTGCTGCTCAGCACCTTCAGCGGAGACCGCCGCTTCTCCCGATTTGGTGGCGTTCTGCAC 2169  
2221 CTGCTGCTCAGCACCTTCAGCGGAGACCGCCGCTTCTCCCGATTTGGTGGCGTTCTGCAC 2280  
456 CTGCTGCTCAGCACCTTCAGCGGAGACCGCCGCTTCTCCCGATTTGGTGGCGTTCTGCAC 515  
2170 TTGAGTGACCTGGATGATGATGGCTTAGATGAAATCATCATGGCAGCCCCCTGAGGATA 2229  
2281 TTGAGTGACCTGGATGATGATGGCTTAGATGAAATCATCATGGCAGCCCCCTGAGGATA 2340  
516 TTGAGTGACCTGGATGATGATGGCTTAGATGAAATCATCATGGCAGCCCCCTGAGGATA 575



6/20

## Figure 2 continued

2230 GCAGATGTAACCTCTGGACTGATTGGGGGAGAAGACGGCCGAGTATATGTATATAATGGC 2289  
2341 GCAGATGTAACCTCTGGACTGATTGGGGGAGAAGACGGCCGAGTATATGTATATAATGGC 2400  
576 GCAGATGTAACCTCTGGACTGATTGGGGGAGAAGACGGCCGAGTATATGTATATAATGGC 635

2290 AAAGAGACCACCCTTGGTGACATGACTGGCAAATGCAAATCATGGATAACTCCATGTCCA 2349  
2401 AAAGAGACCACCCTTGGTGACATGACTGGCAAATGCAAATCATGGATAACTCCATGTCCA 2460  
636 AAAGAGACCACCCTTGGTGACATGACTGGCAAATGCAAATCATGGATAACTCCATGTCCA 695

2350 GAAGAAAAGGCCCAATATGTATTGATTTCTCCTGAAGCCAGCTCAAGGTTTGGGAGCTCC 2409  
2461 GAAGAAAAGGCCCAATATGTATTGATTTCTCCTGAAGCCAGCTCAAGGTTTGGGAGCTCC 2520  
696 GAAGAAAAGGCCCAATATGTATTGATTTCTCCTGAAGCCAGCTCAAGGTTTGGGAGCTCC 755

2410 CTCATCACCGTGAGGTCCAAGGCAAAGAACCAAGTCGTCATTGCTGCTGGAAGGAGTTCT 2469  
2521 CTCATCACCGTGAGGTCCAAGGCAAAGAACCAAGTCGTCATTGCTGCTGGAAGGAGTTCT 2580  
756 CTCATCACCGTGAGGTCCAAGGCAAAGAACCAAGTCGTCATTGCTGCTGGAAGGAGTTCT 815

2470 TTGGGAGCCCGACTCTCCGGGGCACTTCACGTCTATAGCCTTGGCTCAGATTGAAGATTT 2529  
2581 TTGGGAGCCCGACTCTCCGGGGCACTTCACGTCTATAGCCTTGGCTCAGATTGAAGATTT 2640  
816 TTGGGAGCCCGACTCTCCGGGGCACTTCACGTCTATAGCCTTGGCTCAGATTGAAGATTT 875

2530 CACTGCATTTCCCCACTCTGCCCCACCTCTCTCATGCTGAATCACATCCATGGTGAGCATT 2589  
2641 CACTGCATTTCCCCACTCTGCCCCACCTCTCTCATGCTGAATCACATCCATGGTGAGCATT 2700  
876 CACTGCATTTCCCCACTCTGCCCCACCTCTCTCATGCTGAATCACATCCATGGTGAGCATT 935

2590 TTGATGGACAAAGTGGCACATCCAGTGGAGCGGTGGTAGATCCTGATAGACATGGGGCTC 2649  
2701 TTGATGGACAAAGTGGCACATCCAGTGGAGCGGTGGTAGATCCTGATAGACATGGGGCTC 2760  
936 TTGATGGACAAAGTGGCACATCCAGTGGAGCGGTGGTAGATCCTGATAGACATGGGGCTC 995

2650 CTGGGA----- 2655  
2761 CTGGGA----- 2766  
996 CTGGGACAGTGAACCCGATCTGGTCATCGGCTCCCCTTTTGCACCAGGTGGAGGGAAGCA 1055

2656 -----GTAGAGAGACACACTAACAGCCACACCCTCTG 2687  
2767 -----GTAGAGAGACACACTAACAGCCACACCCTCTG 2798  
1056 GAAGGGAATTGTGGCTGCGTTTTATTGAGTAGAGAGACACACTAACAGCCACACCCTCTG 1115

2688 GAAATCTGATACAGTAAATATATGACTGCACCAGAAATATGTGAAATAGCAGACATTCTG 2747  
2799 GAAATCTGATACAGTAAATATATGACTGCACCAG----- 2833  
1116 GAAATCTGATACAGTAAATATATGACTACACCAGAAATATGTGAAATAGCAGACATTCTG 1175

2748 CTTACTCATGTCTCCTTCCACAGTTTACTTCCTCGCTCCCTTTGCATCTAAACCTTTCTT 2807  
-----  
1176 CTTACTCATGTCTCCTTCCACAGTTTACTTCCTCGCTCCCTTTGCATCTAAACCTTTCTT 1235  
-----

2808 CTTTCCCAACTTATTGCCTGTAGTCAGACCTGCTGTACAACCTATTTCTCTTCTCTTG 2867  
-----  
1236 CTTTCCCAACTTATTGCCTGTAGTC----- 1261  
-----

2868 AATGTCTTTCCAGTGGCTGGAAAGGTCCCTCTGTGGTTATCTGTTAGAACAGTCTCTGTA 2927  
-----  
-----

7/20

**Figure 2 continued**

2928 CACAATTCCTCCTAAAAACATCCTTTTTTAAAAAAGAATTGTTTCAGCCATAAAGAAAGA 2987  
-----  
-----

2988 ACAAGATCATGCCCTTTGCAGGGACATGGATGGAGCTGGAGGCCATTATCCTTCATAAAC 3047  
-----  
-----

3048 TATTGCAGGAACAGAAAACCAAACTCCATATTCTCACTTGTAAGTGGGAGCTAAGTGA 3107  
-----  
-----

3108 GAACACGTGGACACATAGAGGGAAACAACACACACTGGGGCCTATGAGAGGGCGGAAGGT 3167  
-----  
-----

3168 GGGAGGAGGGGAGAGATCAGGAAAAATAACTAATGGATACTTAGGGTGATGAAATAATCTG 3227  
-----  
-----

3228 TGTAACAAACCCCCATGACACACCTTTATGTATGTAACAAACCAGCACTTCCTGCGCATG 3287  
-----  
-----

3288 TACCCCTGAACTTAAAAGTTAAAAAAAAGTTGAACTTAAAAATAACAGATTGGCCCATGC 3347  
-----  
-----

3348 CAATCAAAGTATAATAGAAAGCATAGTATAC 3378  
-----  
-----

8/20

**Figure 3****cDNA clone d3**

MILLFQDSMSFIYKALERNIRTMFIGGSQLSQKHVSSPLASYFLSFPYARLGWAMTSADL  
NQDGHGDLVVGAPGYSRPGHIHIGRVYLIYGNLGLPPVDLDDLDKEAHRILEGFQPSGRF  
GSALAVLDFNVDGVPDLAVGAPSVGSEQLTKGAVYVYFGSKQGGMSSSPNITISCQDIYC  
NLGWTLLAADVNGDSEPDLVIGSPFAPGGGKQKGIWAAYFSGPSLSDKEKLNVEAANWTV  
RGEEDFSWFGYSLHGVTVDNRTLLLVGSPTWKNASRLGHLLHIRDEKKS LGRVYGYFPPN  
GQSWFTISGDKAMGKLGTSLSSGHVLMNGTLKQVLLVGAPTYDDVSKVAFLT VTLHQGGA  
TRMYALISDAQPLLLSTFSGDRRFSRFGGVLHLSDDLDDGLDEI IMAAPLRIADVTSGLI  
GGEDGRVYVYNGKETTLGDMTGKCKSWITPCPEEKAQYVLISPEASSRFGSSLITVRSKA  
KNQVVIAAGRSSLGARLSGALHVYSLGSD

**cDNA clone b2**

MSAFRLWPGLLIMLGSLCHRGSPCGLSTHIEIGHRALEFLQLHNGRVNYRELLLEHODAY  
QAGIVFPDCFYPSICKGGKFHDVSESTHWTPFLNASVHYIRENYPLPWEKDTEKLVAFLF  
GITSHMAADVSWHSLGLEQGFRLTMGAIDFHGSYSEAHSAAGDFGGDVLSQFEFNFNYLAR  
RWYVPVKDLLGIYEKLYGRKVITENVIVDCSHIQFLEMYGEMLA VSKLYPTYSTKSPFLV  
EQFQEYFLGGLDDMAFWSTNIYHLTSFMLENGTSDCNLPENPLFIACGGQQNHTQGS KMQ  
KNDFHRNLTTSLTESVDRNIN YTERGVFFSVNSWTPDMSMSFIYKALERNIRTMFIGGSQ  
S QKHVSSPLASYFLSFPYARLGWAMTSADLNQDGHGDLVVGAPGYSRPGHIHIGRVYLIY  
GNDLGLPPVDLDDLDKEAHRILEGFQPSGRFGSALAVLDFNVDGVPDLAVGAPSVGSEQLT  
YKGAVYVYFGSKQGGMSSSPNITISCQDIYCNLGTLLAADVNGDSEPD LVIGSPFAPGG  
GKQKGIWAAYFSGPSLSDKEKLNVEAANWTVRGEEDFSWFGYSLHGVTVDNRTLLLVGSP  
TWKNASRLGHLLHIRDEKKS LGRVYGYFPPNGQSWFTISGDKAMGKLGTSLSSGHVLMNG  
TLKQVLLVGAPTYDDVSKVAFLT VTLHQGGATRMYALISDAQPLLLSTFSGDRRFSRFGG  
VLHLSDDLDDGLDEI IMAAPLRIADVTSGLIGGEDGRVYVYNGKETTLGDMTGKCKSWIT  
PCPEEKVSEKKKKKK

**cDNA clone a1**

MSAFRLWPGLLIMLGSLCHRGSPCGLSTHIEIGHRALEFLQLHNGRVNYRELLLEHODAY  
QAGIVFPDCFYPSICKGGKFHDVSESTHWTPFLNASVHYIRENYPLPWEKDTEKLVAFLF  
GITSHMAADVSWHSLGLEQGFRLTMGAIDFHGSYSEAHSAAGDFGGDVLSQFEFNFNYLAR  
RWYVPVKDLLGIYEKLYGRKVITENVIVDCSHIQFLEMYGEMLA VSKLYPTYSTKSPFLV  
EQFQEYFLGGLDDMAFWSTNIYHLTSFMLENGTSDCNLPENPLFIACGGQQNHTQGS KMQ  
KNDFHRNLTTSLTESVDRNIN YTERGVFFSVNSWTPDMSMSFIYKALERNIRTMFIGGSQ  
S QKHVSSPLASYFLSFPYARLGWAMTSADLNQDGHGDLVVGAPGYSRPGHIHIGRVYLIY  
GNDLGLPPVDLDDLDKEAHRILEGFQPSGRFGSALAVLDFNVDGVPDLAVGAPSVGSEQLT  
YKGAVYVYFGSKQGGMSSSPNITISCQDIYCNLGTLLAADVNGDSEPD LVIGSPFAPGG  
GKQKGIWAAYFSGPSLSDKEKLNVEAANWTVRGEEDFSWFGYSLHGVTVDNRTLLLVGSP  
TWKNASRLGHLLHIRDEKKS LGRVYGYFPPNGQSWFTISGDKAMGKLGTSLSSGHVLMNG  
TLKQVLLVGAPTYDDVSKVAFLT VTLHQGGATRMYALISDAQPLLLSTFSGDRRFSRFGG  
VLHLSDDLDDGLDEI IMAAPLRIADVTSGLIGGEDGRVYVYNGKETTLGDMTGKCKSWIT  
PCPEEKAQYVLISPEASSRFGSSLITVRSKAKNQVVIAAGRSSLGARLSGALHVYSLGSD

9/20

## Figure 4

2832 bp: 690 a 688 c 735 g 719 t

```
1  gtgacctgct tagagagaag cgggtgggtct gcacctggat tttggagtcc cagtgtctgt
61  gcagctctga gcattcccac gtcaccagag aagccggtgg gcaatgagag catgtctgct
121 ttcaggttgt ggcctggcct gctgatcatg ttgggttctc tctgccatag aggttcaccg
181 tgtggccttt caacacacat agaaatagga cacagagctc tggagtttct tcagcttcac
241 aatgggcgtg ttaactacag agagctgtta ctagaacacc aggatgcgta tcaggctgga
301 atcgtgtttc ctgattgttt ttaccctagc atctgcaaag gaggaaaatt ccatgatgtg
361 tctgagagca ctcaactggac tccgtttctt aatgcaagcg ttcattatat ccgagagAAC
421 tatcccttcc cctgggagaa ggacacagag aaactggtag ctttcttgtt tgggaattact
481 tctcacatgg cggcagatgt cagctggcat agtctgggccc ttgaacaagg attccttagg
541 accatgggag ctattgattt tcacggctcc tattcagagg ctcatcggc tgggtgattt
601 ggaggagatg tgttgagcca gtttgaattt aattttaatt accttgcacg acgtcggtat
661 gtgccagtca aagatctact gggaatttat gagaaactgt atggtcgaaa agtcatcacc
721 gaaaatgtaa tcgttgattg ttcacatata cagttcttag aaatgtatgg tgagatgcta
781 gctgtttcca agttatatcc cacttactct acaaagtccc cgtttttggg ggaacaattc
841 caagagtatt ttcttgaggg actggatgat atggcatttt ggtccactaa tatttaccat
901 ctaacaagct tcatgttgga gaatgggacc agtgactgca acctgcctga gaacctctg
961 ttcattgcat gtggcggcca gcaaaaccac acccagggct caaaaatgca gaaaaatgat
1021 tttcacagaa atttgactac atccctaact gaaagtgttg acaggaatat aaactatact
1081 gaaagaggag tgttcttttag tgtaaattcc tggaccccggt attccatgtc ctttatctac
1141 aaggctttgg aaaggaacat aaggacaatg ttcataaggg gctctcagtt gtcacaaaag
1201 cagctctcca gccccttagc atcttacttc ttgtcatttc cttatgcgag gcttggctgg
1261 gcaatgacct cagctgacct caaccaggat gggcacgggt acctcgtggg gggcgacca
1321 ggctacagcc gcccggcca catccacatc gggcgcgtgt acctcatcta cggcaatgac
1381 ctgggcctgc cactgttga cctggacctg gacaaggagg cccacaggat ccttgaaggc
1441 ttccagccct caggtcgggt tggctcggcc ttggctgtgt tggactttaa cgtggacggc
1501 gtgcctgacc tggccgtggg agctccctcg gtgggctccg agcagctcac ctacaaaggt
1561 gccgtgtatg tctactttgg ttccaaacaa ggaggaatgt cttcttcccc taacatcacc
1621 atttcttgcc aggacatcta ctgtaacttg ggctggactc tcttggctgc agatgtgaat
1681 ggagacagtg aaccgatctt ggtcatcggc tccccttttg caccaggtgg agggaagcag
1741 aagggaattg tggtcgcgtt ttattctggc ccagcctga gcgacaaaga aaaactgaac
1801 gtggaggcag ccaactggac ggtgagaggc gaggaagact tctcctggtt tggatattcc
1861 cttcacgggtg tcaactgtga caacagaacc ttgctgttgg ttgggagccc gacctggaag
1921 aatgccagca ggctgggcca tttgttacac atccgagatg agaaaaagag ccttgggagg
1981 gtgtatggct acttcccacc aaacggccaa agctggttta ccatttctgg agacaaggca
2041 atggggaaac tgggtacttc cctttccagt ggccacgtac tgatgaatgg gactctgaa
2101 caagtgtctg tgggtggagc ccctacgtac gatgacgtgt ctaaggtggc attcctgacc
2161 gtgaccttac accaaggcgg agccactcgc atgtacgcac tcatatctga cgcgcagcct
2221 ctgctgtcga gcaccttcag cggagaccgc cgcttctccc gatttgggtgg cgttctgcac
2281 ttgagtgacc tggatgatga tggcttagat gaaatcatca tggcagcccc cctgaggata
2341 gcagatgtaa cctctggact gattggggga gaagacggcc gagtatatgt atataatggc
2401 aaagagacca cccttggtga catgactggc aaatgcaaact catggataac tccatgtcca
2461 gaagaaaagg cccaatatgt attgatttct cctgaagcca gctcaagggt tgggagctcc
2521 ctcatcaccg tgaggtccaa ggcaaagaac caagtcgtca ttgctgctgg aaggagttct
2581 ttgggagccc gactctccgg ggcacttcac gtctatagcc ttggctcaga ttgaagattt
2641 cactgcattt cccactctg cccacctctc tcatgctgaa tcacatccat ggtgagcatt
2701 ttgatggaca aagtggcaca tccagtggag cgggtggtaga tccctgataga catggggctc
2761 ctgggagtag agagacacac taacagccac accctctgga aatctgatac agtAAatata
2821 tgactgcacc ag
```

10/20

## Figure 5

2472 bp: 617 a 588 c 639 g 628 t

```
1  gtctgcacct ggatttttga gtcccagtgc tgetgcagct ctgagcattc ccacgtcacc
61 agagaagccg gtgggcaatg agagcatgtc tgccttcagg ttgtggcctg gcctgtgat
121 catgttgggt tctctctgcc atagagggtc accgtgtggc ctttcaacac acatagaaat
181 aggacacaga gctctggagt ttcttcagct tcacaatggg cgtgttaact acagagagct
241 gttactagaa caccaggatg cgtatcaggc tggaaatcgtg tttcctgatt gtttttacct
301 tagcatctgc aaaggaggaa aattccatga tgtgtctgag agcactcact ggactccggt
361 tcttaatgca agcgttcatt atatccgaga gaactatccc ctccctggg agaaggacac
421 agagaaaactg gtagctttct tgtttggaat tacttctcac atggcggcag atgtcagctg
481 gcatagtctg ggccttgaac aaggattcct taggaccatg ggagctattg attttcacgg
541 ctccatttca gaggtcatt cggtcgttga ttttggagga gatgtgttga gccagtttga
601 atttaatttt aattaccttg cacgacgtg gtatgtgcca gtcaaagatc tactgggaat
661 ttatgagaaa ctgtatggtc gaaaagtcac caccgaaaat gtaatcgttg attgttcaca
721 tatccagttc ttagaaatgt atggtgagat gctagctgtt tccaagttat atcccactta
781 ctctacaaag tccccgtttt tgggtggaaca attccaagag tattttcttg gaggactgga
841 tgatatggca ttttgggtcca ctaatattta ccatctaaca agcttcattg tggagaatgg
901 gaccagtgc tgcaacctgc ctgagaacct tctgttcatt gcatgtggcg gccagcaaaa
961 ccacaccag ggctcaaaaa tgcagaaaaa tgattttcac agaaatttga ctacatccct
1021 aactgaaagt gttgacagga atataaacta tactgaaaga ggagtgttct ttagtgtaaa
1081 ttcctggacc cggattcca tgcctttat ctacaaggct ttggaaagga acataaggac
1141 aatgttcata ggtggctctc agttgtcaca aaagcacgtc tccagccct tagcatctta
1201 cttcttgtca tttccttatg cgaggcttgg ctgggcaatg acctcagctg acctcaacca
1261 ggatgggac ggtgacctcg tgggtggcgc accaggctac agccgccccg gccacatcca
1321 catcgggcgc gtgtacctca tctacggcaa tgacctgggc ctgccacctg ttgacctgga
1381 cctggacaag gagggccaca ggatccttga aggttccag ccctcaggtc ggtttggctc
1441 ggccttggct gtgttggaact ttaacgtgga cggcgtgcct gacctggcog tgggagctcc
1501 ctcggtgggc tccgagcagc tcacctacaa aggtgccgtg tatgtctact ttggttccaa
1561 acaaggagga atgtcttctt cccctaacat caccatttct tgccaggaca tctactgtaa
1621 cttgggctgg actctcttgg ctgcagatgt gaatggagac agtgaacctg atctggctcat
1681 cggctccctt tttgcaccag gtggagggaa gcagaaggga attgtggctg cgttttatcc
1741 tggccccagc ctgagcgaca aagaaaaact gaacgtggag gcagccaact ggacggtgag
1801 aggcgaggaa gacttctcct ggttttgata ttccttcac ggtgtcactg tggacaacag
1861 aaccttgctg ttggttggga gcccagctg gaagaatgcc agcaggctgg gccatttgtt
1921 acacatccga gatgagaaaa agagccttgg gaggtgtat ggctacttcc caccaaacgg
1981 ccaaagctgg tttaccattt ctggagacaa ggcaatgggg aaactgggta cttcccttcc
2041 cagtggccac gtactgatga atgggactct gaaacaagtg ctgctggttg gagccctac
2101 gtacgatgac gtgtctaagg tggcattcct gaccgtgacc ctacaccaag ggggagcac
2161 tcgcatgtac gcaactcatat ctgacgcga gcctctgctg ctgagcactc tcagcggaga
2221 ccgcgcttcc tcccgatatt gtggcggttct gcaacttgagt gacctggatg atgatggctt
2281 agatgaaatc atcatggcag cccccctgag gatagcagat gtaacctctg gactgattgg
2341 gggagaagac ggccgagtat atgtatataa tggcaaagag accacccttg gtgacatgac
2401 tggcaaatgc aaatcatgga taactccatg tccagaagaa aaggttaagtg aaaaaaaaaa
2461 aaaaaaaaaa aa
```

11/20

## Figure 6

1942 bp: 455 a 496 c 502 g 489 t

```

1  gggctgtaac tctgccatcc ctcagcataa tttgggggta tgatttcact atcctaattg
61 cctgtcctaa gtgatccttac ttgctgatag gacctaatgt tttattttat tgtttagcac
121 ttctaaaaac tcatttcctt tacacaagtc caatactttg gacaggaaac agtagctttg
181 ttgattatgc tacgtgtcctt tactgtctat aatgattcct ttatttcagg attccatgtc
241 ctttatctac aaggcttttg aaaggaacat aaggacaatg ttcatagggt gctctcagtt
301 gtcacaaaag cacgtctcca gccccttagc atcttacttc ttgtcatttc cttatgcgag
361 gcttggctgg gcaatgacct cagctgacct caaccaggat gggcacgggt acctcgtggt
421 gggcgcacca ggctacagcc gccccggcca catccacatc gggcgcggtg acctcatcta
481 cggcaatgac ctgggcctgc cacctgttga cctggacctg gacaaggagg cccacaggat
541 ccttgaaggc ttccagccct caggctcggtt tggtcgggcc ttggctgtgt tggactttaa
601 cgtggagcgg gtgcctgacc tggccgtggg agtccctcg gtgggctccg agcagctcac
661 ctacaaaggt gccgtgtatg tctactttgg ttccaaacaa ggaggaatgt cttcttcccc
721 taacatcacc atttcttgcc aggacatcta ctgtaacttg ggctggactc tcttggtg
781 agatgtgaat ggagacagtg aacccgatct ggctatcggc tccccttttg caccaggtgg
841 agggaagcag aagggaattg tggctgcgtt ttattctggc cccagcctga ggcacaaaga
901 aaaactgaac gtggaggcag ccaactggac ggtgagaggc gaggaagact tctcctggtt
961 tggatattcc cttcacgggtg tcactgtgga caacagaacc ttgctgttgg ttgggagccc
1021 gacctggaag aatgccagca ggctgggcca tttgttacac atccgagatg agaaaaagag
1081 ccttggggagg gtgtatggct acttcccacc aaacggccaa agctggttta ccatttctgg
1141 agacaaggca atggggaaac tgggtacttc cttttccagt ggccacgtac tgatgaatgg
1201 gactctgaaa caagtgtctg tgggtggagc ccttacgtac gatgacgtgt ctaaggtggc
1261 attcctgacc gtgaccttac accaaggcgg agccactcgc atgtacgcac tcatatctga
1321 cgcgcagcct ctgctgctca gcaccttcag cggagaccgc cgcttctccc gatttggtgg
1381 cgttctgcac ttgagtgacc tggatgatga tggcttagat gaaatcatca tggcagcccc
1441 cctgaggata gcagatgtaa cctctggact gattggggga gaagacggcc gagtatatgt
1501 atataatggc aaagagacca cccttgggtga catgactggc aaatgcaaat catggataac
1561 tccatgtcca gaagaaaagg cccaatatgt attgatttct cctgaagcca gctcaagggt
1621 tgggagctcc ctcacaccg tgagggtcaa ggcaaagaac caagtcgtca ttgctgctgg
1681 aaggagttct ttgggagccc gactctccgg ggcacttcac gtctatagcc ttggctcaga
1741 ttgaagattt cactgcattt cccactctg cccacctctc tcatgctgaa tcacatccat
1801 ggtgagcatt ttgatggaca aagtggcaca tccagtggag cgggtggtaga tcctgataga
1861 catggggctc ctgggagtag agagacacac taacagccac accctctgga aatctgatac
1921 agtaaatata tgactgcacc ag

```

12/20

Figure 7

database	MSAFRLWPGLLIMLGSLCHRGSPCGLSTHVEIGHRALEFLQLHNGRVNYRELLLEHQDAY	60
d3	-----	
b2	MSAFRLWPGLLIMLGSLCHRGSPCGLSTHVEIGHRALEFLQLHNGRVNYRELLLEHQDAY	60
a1	MSAFRLWPGLLIMLGSLCHRGSPCGLSTHVEIGHRALEFLQLHNGRVNYRELLLEHQDAY	60
database	QAGIVFPDCFYPSICKGGKFHDVSESTHWTPLNASVHYIRENYPLPWEKDTEKLVAFLF	120
d3	-----	
b2	QAGIVFPDCFYPSICKGGKFHDVSESTHWTPLNASVHYIRENYPLPWEKDTEKLVAFLF	120
a1	QAGIVFPDCFYPSICKGGKFHDVSESTHWTPLNASVHYIRENYPLPWEKDTEKLVAFLF	120
database	GITSHMAADVSWHSLGLEQGFRLTMGAIDFHGSYSEAHSAAGDFGGDVLSQFEFNFNYLAR	180
d3	-----	
b2	GITSHMAADVSWHSLGLEQGFRLTMGAIDFHGSYSEAHSAAGDFGGDVLSQFEFNFNYLAR	180
a1	GITSHMAADVSWHSLGLEQGFRLTMGAIDFHGSYSEAHSAAGDFGGDVLSQFEFNFNYLAR	180
database	RWYVPVKDLLGIYEKLYGRKVITENVIVDCSHIQFLEMYGEMLA VSKLYPTYSTKSPFLV	240
d3	-----	
b2	RWYVPVKDLLGIYEKLYGRKVITENVIVDCSHIQFLEMYGEMLA VSKLYPTYSTKSPFLV	240
a1	RWYVPVKDLLGIYEKLYGRKVITENVIVDCSHIQFLEMYGEMLA VSKLYPTYSTKSPFLV	240
database	EQFQEYFLGGLDDMAFWSTNIYHLTIFMLENGTSDCNLPENPLFIACGGQQNHTQGSKMQ	300
d3	-----	
b2	EQFQEYFLGGLDDMAFWSTNIYHLTIFMLENGTSDCNLPENPLFIACGGQQNHTQGSKMQ	300
a1	EQFQEYFLGGLDDMAFWSTNIYHLTIFMLENGTSDCNLPENPLFIACGGQQNHTQGSKMQ	300
database	KNDFHRNLTTSLTESVDRNINYTERGVFFSVNSWTPDMSFSFIYKALERNIRT MFIGGSQ L	360
d3	-----MILLFQDSMSFSFIYKALERNIRT MFIGGSQ L	30
b2	KNDFHRNLTTSLTESVDRNINYTERGVFFSVNSWTPDMSFSFIYKALERNIRT MFIGGSQ L	360
a1	KNDFHRNLTTSLTESVDRNINYTERGVFFSVNSWTPDMSFSFIYKALERNIRT MFIGGSQ L	360
database	SQKHVSSPLASYFLSFPYARLGWAMTSADLNQDGHGDLVVGAPGYSRPGHIHIGRVYLIY	420
d3	SQKHVSSPLASYFLSFPYARLGWAMTSADLNQDGHGDLVVGAPGYSRPGHIHIGRVYLIY	90
b2	SQKHVSSPLASYFLSFPYARLGWAMTSADLNQDGHGDLVVGAPGYSRPGHIHIGRVYLIY	420
a1	SQKHVSSPLASYFLSFPYARLGWAMTSADLNQDGHGDLVVGAPGYSRPGHIHIGRVYLIY	420
database	GNDLGLPPVDLDLDKEAHRILEGFQPSGRFGSALAVLDFNVDGVPDLAVGAPSVGSEQLT	480
d3	GNDLGLPPVDLDLDKEAHRILEGFQPSGRFGSALAVLDFNVDGVPDLAVGAPSVGSEQLT	150
b2	GNDLGLPPVDLDLDKEAHRILEGFQPSGRFGSALAVLDFNVDGVPDLAVGAPSVGSEQLT	480
a1	GNDLGLPPVDLDLDKEAHRILEGFQPSGRFGSALAVLDFNVDGVPDLAVGAPSVGSEQLT	480
database	YKGAVYVYFGSKQGGMSSSPNITISCQDIYCNLGTLLAADVNGDSEPDLVIGSPFAPGG	540
d3	YKGAVYVYFGSKQGGMSSSPNITISCQDIYCNLGTLLAADVNGDSEPDLVIGSPFAPGG	210
b2	YKGAVYVYFGSKQGGMSSSPNITISCQDIYCNLGTLLAADVNGDSEPDLVIGSPFAPGG	540
a1	YKGAVYVYFGSKQGGMSSSPNITISCQDIYCNLGTLLAADVNGDSEPDLVIGSPFAPGG	540

13/20

## Figure 7 continued

database	GKQKGIVAAFYSGPSLSDKEKLNVEAANWTVRGEEDFSWFGYSLHGVTVDNRTLLLVGSP	600
d3	GKQKGIVAAFYSGPSLSDKEKLNVEAANWTVRGEEDFSWFGYSLHGVTVDNRTLLLVGSP	270
b2	GKQKGIVAAFYSGPSLSDKEKLNVEAANWTVRGEEDFSWFGYSLHGVTVDNRTLLLVGSP	600
a1	GKQKGIVAAFYSGPSLSDKEKLNVEAANWTVRGEEDFSWFGYSLHGVTVDNRTLLLVGSP	600
database	TWKNASRLGHLHLHIRDEKKS LGRVYGYFPPNGQSWFTISGDKAMGKLGTSLSSGHVLMNG	660
d3	TWKNASRLGHLHLHIRDEKKS LGRVYGYFPPNGQSWFTISGDKAMGKLGTSLSSGHVLMNG	330
b2	TWKNASRLGHLHLHIRDEKKS LGRVYGYFPPNGQSWFTISGDKAMGKLGTSLSSGHVLMNG	660
a1	TWKNASRLGHLHLHIRDEKKS LGRVYGYFPPNGQSWFTISGDKAMGKLGTSLSSGHVLMNG	660
database	TLKQVLLVGAPTYDDVSKVAFLT VTLHQGGATRMALISDAQPLLLSTFSGDRRFSRFGG	720
d3	TLKQVLLVGAPTYDDVSKVAFLT VTLHQGGATRMALISDAQPLLLSTFSGDRRFSRFGG	390
b2	TLKQVLLVGAPTYDDVSKVAFLT VTLHQGGATRMALISDAQPLLLSTFSGDRRFSRFGG	720
a1	TLKQVLLVGAPTYDDVSKVAFLT VTLHQGGATRMALISDAQPLLLSTFSGDRRFSRFGG	720
database	VLHLSDLDDGLDEI IMAAPLRIADVTSGLIGGEDGRVYVYNGKETTLGDMTGKCKSWIT	780
d3	VLHLSDLDDGLDEI IMAAPLRIADVTSGLIGGEDGRVYVYNGKETTLGDMTGKCKSWIT	450
b2	VLHLSDLDDGLDEI IMAAPLRIADVTSGLIGGEDGRVYVYNGKETTLGDMTGKCKSWIT	780
a1	VLHLSDLDDGLDEI IMAAPLRIADVTSGLIGGEDGRVYVYNGKETTLGDMTGKCKSWIT	780
database	PCPEEKAQYVLISPEASSRFGSS LITVRSKAKNQVVIAAGRSSLGARLSGALHVYSLGSD	840
d3	PCPEEKAQYVLISPEASSRFGSS LITVRSKAKNQVVIAAGRSSLGARLSGALHVYSLGSD	510
b2	PCPEEKVSEKKKKK-----	795
a1	PCPEEKAQYVLISPEASSRFGSS LITVRSKAKNQVVIAAGRSSLGARLSGALHVYSLGSD	840
Database	840 aa	
d3	510 aa	
b2	795 aa	
a1	840 aa	



14/20

**Figure 8**

- 1: pancreatic-form: cDNA sequence from GenBank database (L11702)  
 2: cDNA clone A1  
 3: cDNA clone B2  
 4: cDNA clone D3

1	GTGACCTGCTTAGAGAGAAGCGGTGGGTCTGCACCTGGATTTTGGAGTCCCAGTGCTGCT	60
1	-----GTCTGCACCTGGATTTTGGAGTCCCAGTGCTGCT	34
1	-----ATGTCCTGCT	9
61	GCAGCTCTGAGCATTCCCACGTCACCAGAGAAGCCGGTGGGCAATGAGAGCATGTCTGCT	120
35	GCAGCTCTGAGCATTCCCACGTCACCAGAGAAGCCGGTGGGCAATGAGAGCATGTCTGCT	94
10	TTCAGGTTGTGGCCTGGCCTGCTGATCATGTTGGGTTCTCTCTGCCATAGAGGTTACCG	69
121	TTCAGGTTGTGGCCTGGCCTGCTGATCATGTTGGGTTCTCTCTGCCATAGAGGTTACCG	180
95	TTCAGGTTGTGGCCTGGCCTGCTGATCATGTTGGGTTCTCTCTGCCATAGAGGTTACCG	154
70	TGTGGCCTTTCAACACACGTCAGAAATAGGACACAGAGCTCTGGAGTTTCTTCAGCTTCAC	129
181	TGTGGCCTTTCAACACACATAGAAATAGGACACAGAGCTCTGGAGTTTCTTCAGCTTCAC	240
155	TGTGGCCTTTCAACACACATAGAAATAGGACACAGAGCTCTGGAGTTTCTTCAGCTTCAC	214
130	AATGGGCGTGTTAACTACAGAGAGCTGTTACTAGAACACCAGGATGCGTATCAGGCTGGA	189
241	AATGGGCGTGTTAACTACAGAGAGCTGTTACTAGAACACCAGGATGCGTATCAGGCTGGA	300
215	AATGGGCGTGTTAACTACAGAGAGCTGTTACTAGAACACCAGGATGCGTATCAGGCTGGA	274
190	ATCGTGTTTCCTGATTGTTTTTACCCTAGCATCTGCAAAGGAGGAAAATTCCATGATGTG	249
301	ATCGTGTTTCCTGATTGTTTTTACCCTAGCATCTGCAAAGGAGGAAAATTCCATGATGTG	360
275	ATCGTGTTTCCTGATTGTTTTTACCCTAGCATCTGCAAAGGAGGAAAATTCCATGATGTG	334
250	TCTGAGAGCACTCACTGGACTCCGTTTCTTAATGCAAGCGTTCATTATATCCGAGAGAAAC	309
361	TCTGAGAGCACTCACTGGACTCCGTTTCTTAATGCAAGCGTTCATTATATCCGAGAGAAAC	420
335	TCTGAGAGCACTCACTGGACTCCGTTTCTTAATGCAAGCGTTCATTATATCCGAGAGAAAC	394
310	TATCCCCCTTCCCTGGGAGAAGGACACAGAGAACTGGTAGCTTTCTTGTTTGGGAATTACT	369
421	TATCCCCCTTCCCTGGGAGAAGGACACAGAGAACTGGTAGCTTTCTTGTTTGGGAATTACT	480
395	TATCCCCCTTCCCTGGGAGAAGGACACAGAGAACTGGTAGCTTTCTTGTTTGGGAATTACT	454
370	TCTCACATGGCGGCAGATGTCAGCTGGCATAGTCTGGGCCTTGAACAAGGATTCCTTAGG	429
481	TCTCACATGGCGGCAGATGTCAGCTGGCATAGTCTGGGCCTTGAACAAGGATTCCTTAGG	540
541	TCTCACATGGCGGCAGATGTCAGCTGGCATAGTCTGGGCCTTGAACAAGGATTCCTTAGG	514

15/20

## Figure 8 continued

430	ACCATGGGAGCTATTGATTTTCACGGCTCCTATTTCAGAGGCTCATTTCGGCTGGTGATTTT	489
541	ACCATGGGAGCTATTGATTTTCACGGCTCCTATTTCAGAGGCTCATTTCGGCTGGTGATTTT	600
515	ACCATGGGAGCTATTGATTTTCACGGCTCCTATTTCAGAGGCTCATTTCGGCTGGTGATTTT	574
-----		
490	GGAGGAGATGTGTTGAGCCAGTTTGAATTTAATTTTAATTACCTTGCACGACGCTGGTAT	549
601	GGAGGAGATGTGTTGAGCCAGTTTGAATTTAATTTTAATTACCTTGCACGACGCTGGTAT	660
575	GGAGGAGATGTGTTGAGCCAGTTTGAATTTAATTTTAATTACCTTGCACGACGCTGGTAT	634
-----		
550	GTGCCAGTCAAAGATCTACTGGGAATTTATGAGAACTGTATGGTCGAAAAGTCATCACC	609
661	GTGCCAGTCAAAGATCTACTGGGAATTTATGAGAACTGTATGGTCGAAAAGTCATCACC	720
635	GTGCCAGTCAAAGATCTACTGGGAATTTATGAGAACTGTATGGTCGAAAAGTCATCACC	694
-----		
610	GAAAATGTAATCGTTGATTGTTTCACATATCCAGTTCTTAGAAATGTATGGTGAGATGCTA	669
721	GAAAATGTAATCGTTGATTGTTTCACATATCCAGTTCTTAGAAATGTATGGTGAGATGCTA	780
695	GAAAATGTAATCGTTGATTGTTTCACATATCCAGTTCTTAGAAATGTATGGTGAGATGCTA	754
-----		
670	GCTGTTTCCAAGTTATATCCCACTTACTCTACAAAGTCCCCGTTTTTGGTGGAACAATTC	729
781	GCTGTTTCCAAGTTATATCCCACTTACTCTACAAAGTCCCCGTTTTTGGTGGAACAATTC	840
755	GCTGTTTCCAAGTTATATCCCACTTACTCTACAAAGTCCCCGTTTTTGGTGGAACAATTC	814
-----		
730	CAAGAGTATTTTCTTGGAGGACTGGATGATATGGCATTTTGGTCCACTAATATTTACCAT	789
841	CAAGAGTATTTTCTTGGAGGACTGGATGATATGGCATTTTGGTCCACTAATATTTACCAT	900
815	CAAGAGTATTTTCTTGGAGGACTGGATGATATGGCATTTTGGTCCACTAATATTTACCAT	874
-----GGGCTGTAAC		10
-----		
790	CTAACAATCTTCATGTTGGAGAATGGGACCAGTGACTGCAACCTGCCTGAGAACCCCTCTG	849
901	CTAACAAGCTTCATGTTGGAGAATGGGACCAGTGACTGCAACCTGCCTGAGAACCCCTCTG	960
875	CTAACAAGCTTCATGTTGGAGAATGGGACCAGTGACTGCAACCTGCCTGAGAACCCCTCTG	934
11	TCTGCCATCCCTCAGCATAATTTGGGGGTATGATTTCACTATCCTAATTGCCTGTCTTAA	70
-----		
850	TTCATTGCATGTGGCGGCCAGCAAAACCACACCCAGGGCTCAAAAATGCAGAAAAATGAT	909
961	TTCATTGCATGTGGCGGCCAGCAAAACCACACCCAGGGCTCAAAAATGCAGAAAAATGAT	1020
935	TTCATTGCATGTGGCGGCCAGCAAAACCACACCCAGGGCTCAAAAATGCAGAAAAATGAT	994
71	GTGATCTTACTTGCTGATAGGACCTAATGTTTTATTTTATTGTTTAGCACTTCTAAAAAC	130
-----		
910	TTTCACAGAAATTTGACTACATCCCTAAGTAAAGTGTTGACAGGAATATAAACTATACT	969
1021	TTTCACAGAAATTTGACTACATCCCTAAGTAAAGTGTTGACAGGAATATAAACTATACT	1080
995	TTTCACAGAAATTTGACTACATCCCTAAGTAAAGTGTTGACAGGAATATAAACTATACT	1054
131	TCATTTCTTTACACAAGTCCAATACTTTGGACAGGAAACAGTAGCTTTGTTGATTATGC	180
-----		
970	GAAAGAGGAGTGTTCTTTAGTGTAATTCCTGGACCCCGGATTCCATGTCCTTTATCTAC	1029
1081	GAAAGAGGAGTGTTCTTTAGTGTAATTCCTGGACCCCGGATTCCATGTCCTTTATCTAC	1140
1055	GAAAGAGGAGTGTTCTTTAGTGTAATTCCTGGACCCCGGATTCCATGTCCTTTATCTAC	1114
181	TACGTGTCCTTACTGTCTATAATGATTCTTTTATTTTCAGGATTCCATGTCCTTTATCTAC	240

16/20

## Figure 8 continued

1030	AAGGCTTTGGAAAGGAACATAAGGACAATGTTTCATAGGTGGCTCTCAGTTGTCACAAAAG	1089
1141	AAGGCTTTGGAAAGGAACATAAGGACAATGTTTCATAGGTGGCTCTCAGTTGTCACAAAAG	1200
1115	AAGGCTTTGGAAAGGAACATAAGGACAATGTTTCATAGGTGGCTCTCAGTTGTCACAAAAG	1174
241	AAGGCTTTGGAAAGGAACATAAGGACAATGTTTCATAGGTGGCTCTCAGTTGTCACAAAAG	300
1090	CACGTCTCCAGCCCCCTTAGCATCTTACTTCTTGTCATTTCTTATGCGAGGCTTGGCTGG	1149
1201	CACGTCTCCAGCCCCCTTAGCATCTTACTTCTTGTCATTTCTTATGCGAGGCTTGGCTGG	1260
1175	CACGTCTCCAGCCCCCTTAGCATCTTACTTCTTGTCATTTCTTATGCGAGGCTTGGCTGG	1234
301	CACGTCTCCAGCCCCCTTAGCATCTTACTTCTTGTCATTTCTTATGCGAGGCTTGGCTGG	360
1150	GCAATGACCTCAGCTGACCTCAACCAGGATGGGCGACGGTGACCTCGTGGTGGGCGCACCA	1209
1261	GCAATGACCTCAGCTGACCTCAACCAGGATGGGCGACGGTGACCTCGTGGTGGGCGCACCA	1320
1235	GCAATGACCTCAGCTGACCTCAACCAGGATGGGCGACGGTGACCTCGTGGTGGGCGCACCA	1294
361	GCAATGACCTCAGCTGACCTCAACCAGGATGGGCGACGGTGACCTCGTGGTGGGCGCACCA	420
1210	GGCTACAGCCGCCCCGGCCACATCCACATCGGGCGCGTGTACCTCATCTACGGCAATGAC	1269
1321	GGCTACAGCCGCCCCGGCCACATCCACATCGGGCGCGTGTACCTCATCTACGGCAATGAC	1380
1295	GGCTACAGCCGCCCCGGCCACATCCACATCGGGCGCGTGTACCTCATCTACGGCAATGAC	1354
421	GGCTACAGCCGCCCCGGCCACATCCACATCGGGCGCGTGTACCTCATCTACGGCAATGAC	480
1270	CTGGGCCTGCCACCTGTTGACCTGGACCTGGACAAGGAGGCCCCACAGGATCCTTGAAGGC	1329
1381	CTGGGCCTGCCACCTGTTGACCTGGACCTGGACAAGGAGGCCCCACAGGATCCTTGAAGGC	1440
1355	CTGGGCCTGCCACCTGTTGACCTGGACCTGGACAAGGAGGCCCCACAGGATCCTTGAAGGC	1414
481	CTGGGCCTGCCACCTGTTGACCTGGACCTGGACAAGGAGGCCCCACAGGATCCTTGAAGGC	540
1330	TTCCAGCCCTCAGGTCGGTTTGGCTCGGCCTTGGCTGTGTTGGACTTTAACGTGGACGGC	1389
1441	TTCCAGCCCTCAGGTCGGTTTGGCTCGGCCTTGGCTGTGTTGGACTTTAACGTGGACGGC	1500
1415	TTCCAGCCCTCAGGTCGGTTTGGCTCGGCCTTGGCTGTGTTGGACTTTAACGTGGACGGC	1474
541	TTCCAGCCCTCAGGTCGGTTTGGCTCGGCCTTGGCTGTGTTGGACTTTAACGTGGACGGC	600
1390	GTGCCTGACCTGGCCGTGGGAGCTCCCTCGGTGGGCTCCGAGCAGCTCACCTACAAAGGT	1449
1501	GTGCCTGACCTGGCCGTGGGAGCTCCCTCGGTGGGCTCCGAGCAGCTCACCTACAAAGGT	1560
1475	GTGCCTGACCTGGCCGTGGGAGCTCCCTCGGTGGGCTCCGAGCAGCTCACCTACAAAGGT	1534
601	GTGCCTGACCTGGCCGTGGGAGCTCCCTCGGTGGGCTCCGAGCAGCTCACCTACAAAGGT	660
1450	GCCGTGTATGTCTACTTTGGTTCCAAACAAGGAGGAATGTCTTCTTCCCCTAACATCACC	1509
1561	GCCGTGTATGTCTACTTTGGTTCCAAACAAGGAGGAATGTCTTCTTCCCCTAACATCACC	1620
1535	GCCGTGTATGTCTACTTTGGTTCCAAACAAGGAGGAATGTCTTCTTCCCCTAACATCACC	1594
661	GCCGTGTATGTCTACTTTGGTTCCAAACAAGGAGGAATGTCTTCTTCCCCTAACATCACC	720
1510	ATTTCTTGCCAGGACATCTACTGTAACCTTGGGCTGGACTCTCTTGGCTGCAGATGTGAAT	1569
1621	ATTTCTTGCCAGGACATCTACTGTAACCTTGGGCTGGACTCTCTTGGCTGCAGATGTGAAT	1680
1595	ATTTCTTGCCAGGACATCTACTGTAACCTTGGGCTGGACTCTCTTGGCTGCAGATGTGAAT	1654
721	ATTTCTTGCCAGGACATCTACTGTAACCTTGGGCTGGACTCTCTTGGCTGCAGATGTGAAT	780
1570	GGAGACAGTGAACCCGATCTGGTCATCGGCTCCCCTTTTGACCAGGTGGAGGGAAGCAG	1629
1681	GGAGACAGTGAACCCGATCTGGTCATCGGCTCCCCTTTTGACCAGGTGGAGGGAAGCAG	1740
1655	GGAGACAGTGAACCCGATCTGGTCATCGGCTCCCCTTTTGACCAGGTGGAGGGAAGCAG	1714
781	GGAGACAGTGAACCCGATCTGGTCATCGGCTCCCCTTTTGACCAGGTGGAGGGAAGCAG	840

17/20

## Figure 8 continued

1630	AAGGGAATTGTGGCTGCGTTTTATTCTGGCCCCAGCCTGAGCGACAAAGAAAAACTGAAC	1689
1741	AAGGGAATTGTGGCTGCGTTTTATTCTGGCCCCAGCCTGAGCGACAAAGAAAAACTGAAC	1800
1715	AAGGGAATTGTGGCTGCGTTTTATTCTGGCCCCAGCCTGAGCGACAAAGAAAAACTGAAC	1774
841	AAGGGAATTGTGGCTGCGTTTTATTCTGGCCCCAGCCTGAGCGACAAAGAAAAACTGAAC	900
1690	GTGGAGGCAGCCAACCTGGACGGTGAGAGGCGAGGAAGACTTCTCCTGGTTTGGATATTCC	1749
1801	GTGGAGGCAGCCAACCTGGACGGTGAGAGGCGAGGAAGACTTCTCCTGGTTTGGATATTCC	1860
1775	GTGGAGGCAGCCAACCTGGACGGTGAGAGGCGAGGAAGACTTCTCCTGGTTTGGATATTCC	1834
901	GTGGAGGCAGCCAACCTGGACGGTGAGAGGCGAGGAAGACTTCTCCTGGTTTGGATATTCC	960
1750	CTTCACGGTGCTCACTGTGGACAACAGAACCTTGCTGTTGGTTGGGAGCCCGACCTGGAAG	1809
1861	CTTCACGGTGCTCACTGTGGACAACAGAACCTTGCTGTTGGTTGGGAGCCCGACCTGGAAG	1920
1835	CTTCACGGTGCTCACTGTGGACAACAGAACCTTGCTGTTGGTTGGGAGCCCGACCTGGAAG	1894
961	CTTCACGGTGCTCACTGTGGACAACAGAACCTTGCTGTTGGTTGGGAGCCCGACCTGGAAG	1020
1810	AATGCCAGCAGGCTGGGCCATTTGTTACACATCCGAGATGAGAAAAAGAGCCTTGGGAGG	1869
1921	AATGCCAGCAGGCTGGGCCATTTGTTACACATCCGAGATGAGAAAAAGAGCCTTGGGAGG	1980
1895	AATGCCAGCAGGCTGGGCCATTTGTTACACATCCGAGATGAGAAAAAGAGCCTTGGGAGG	1954
1021	AATGCCAGCAGGCTGGGCCATTTGTTACACATCCGAGATGAGAAAAAGAGCCTTGGGAGG	1080
1870	GTGTATGGCTACTTCCCACCAAACGGCCAAAGCTGGTTTACCATTTCTGGAGACAAGGCA	1929
1981	GTGTATGGCTACTTCCCACCAAACGGCCAAAGCTGGTTTACCATTTCTGGAGACAAGGCA	2040
1955	GTGTATGGCTACTTCCCACCAAACGGCCAAAGCTGGTTTACCATTTCTGGAGACAAGGCA	2014
1081	GTGTATGGCTACTTCCCACCAAACGGCCAAAGCTGGTTTACCATTTCTGGAGACAAGGCA	1140
1930	ATGGGGAAACTGGGTACTTCCCTTTCCAGTGGCCACGTAAGTGAATGGGACTCTGAAA	1989
2041	ATGGGGAAACTGGGTACTTCCCTTTCCAGTGGCCACGTAAGTGAATGGGACTCTGAAA	2100
2015	ATGGGGAAACTGGGTACTTCCCTTTCCAGTGGCCACGTAAGTGAATGGGACTCTGAAA	2074
1141	ATGGGGAAACTGGGTACTTCCCTTTCCAGTGGCCACGTAAGTGAATGGGACTCTGAAA	1200
1990	CAAGTGCTGCTGGTTGGAGCCCCCTACGTACGATGACGTGTCTAAGGTGGCATTCTGACC	2049
2101	CAAGTGCTGCTGGTTGGAGCCCCCTACGTACGATGACGTGTCTAAGGTGGCATTCTGACC	2160
2075	CAAGTGCTGCTGGTTGGAGCCCCCTACGTACGATGACGTGTCTAAGGTGGCATTCTGACC	2134
1201	CAAGTGCTGCTGGTTGGAGCCCCCTACGTACGATGACGTGTCTAAGGTGGCATTCTGACC	1260
2050	GTGACCCTACACCAAGGCGGAGCCACTCGCATGTACGCACTCATATCTGACGCGCAGCCT	2109
2161	GTGACCCTACACCAAGGCGGAGCCACTCGCATGTACGCACTCATATCTGACGCGCAGCCT	2220
2135	GTGACCCTACACCAAGGCGGAGCCACTCGCATGTACGCACTCATATCTGACGCGCAGCCT	2194
1261	GTGACCCTACACCAAGGCGGAGCCACTCGCATGTACGCACTCATATCTGACGCGCAGCCT	1320
2110	CTGCTGCTCAGCACCTTCAGCGGAGACCGCCGCTTCTCCCGATTGGTGGCGTTCTGCAC	2169
2221	CTGCTGCTCAGCACCTTCAGCGGAGACCGCCGCTTCTCCCGATTGGTGGCGTTCTGCAC	2280
2195	CTGCTGCTCAGCACCTTCAGCGGAGACCGCCGCTTCTCCCGATTGGTGGCGTTCTGCAC	2254
1321	CTGCTGCTCAGCACCTTCAGCGGAGACCGCCGCTTCTCCCGATTGGTGGCGTTCTGCAC	1380
2170	TTGAGTGACCTGGATGATGATGGCTTAGATGAAATCATCATGGCAGCCCCCTGAGGATA	2229
2281	TTGAGTGACCTGGATGATGATGGCTTAGATGAAATCATCATGGCAGCCCCCTGAGGATA	2340
2255	TTGAGTGACCTGGATGATGATGGCTTAGATGAAATCATCATGGCAGCCCCCTGAGGATA	2314
1381	TTGAGTGACCTGGATGATGATGGCTTAGATGAAATCATCATGGCAGCCCCCTGAGGATA	1440

18/20

## Figure 8 continued

2230 GCAGATGTAACCTCTGGACTGATTGGGGGAGAAGACGGCCGAGTATATGTATATAATGGC 2289  
2341 GCAGATGTAACCTCTGGACTGATTGGGGGAGAAGACGGCCGAGTATATGTATATAATGGC 2400  
2315 GCAGATGTAACCTCTGGACTGATTGGGGGAGAAGACGGCCGAGTATATGTATATAATGGC 2374  
1441 GCAGATGTAACCTCTGGACTGATTGGGGGAGAAGACGGCCGAGTATATGTATATAATGGC 1500

2290 AAAGAGACCACCCTTGGTGACATGACTGGCAAATGCAAATCATGGATAACTCCATGTCCA 2349  
2401 AAAGAGACCACCCTTGGTGACATGACTGGCAAATGCAAATCATGGATAACTCCATGTCCA 2460  
2375 AAAGAGACCACCCTTGGTGACATGACTGGCAAATGCAAATCATGGATAACTCCATGTCCA 2434  
1501 AAAGAGACCACCCTTGGTGACATGACTGGCAAATGCAAATCATGGATAACTCCATGTCCA 1560

2350 GAAGAAAAGGCCCAATATGTATTGATTTCTCCTGAAGCCAGCTCAAGGTTTGGGAGCTCC 2409  
2461 GAAGAAAAGGCCCAATATGTATTGATTTCTCCTGAAGCCAGCTCAAGGTTTGGGAGCTCC 2520  
2435 GAAGAAAAGGTAAGTGAAGAAAAAAAAAAAAAAAAAAAAA----- 2472  
1561 GAAGAAAAGGCCCAATATGTATTGATTTCTCCTGAAGCCAGCTCAAGGTTTGGGAGCTCC 1620

2410 CTCATCACCGTGAGGTCCAAGGCAAAGAACCAAGTCGTCATTGCTGCTGGAAGGAGTTCT 2469  
2521 CTCATCACCGTGAGGTCCAAGGCAAAGAACCAAGTCGTCATTGCTGCTGGAAGGAGTTCT 2580  
-----  
1621 CTCATCACCGTGAGGTCCAAGGCAAAGAACCAAGTCGTCATTGCTGCTGGAAGGAGTTCT 1680

2470 TTGGGAGCCCGACTCTCCGGGGCACTTCACGTCTATAGCCTTGGCTCAGATTGAAGATTT 2529  
2581 TTGGGAGCCCGACTCTCCGGGGCACTTCACGTCTATAGCCTTGGCTCAGATTGAAGATTT 2640  
-----  
1681 TTGGGAGCCCGACTCTCCGGGGCACTTCACGTCTATAGCCTTGGCTCAGATTGAAGATTT 1740

2530 CACTGCATTTCCCCACTCTGCCCACCTCTCTCATGCTGAATCACATCCATGGTGAGCATT 2589  
2641 CACTGCATTTCCCCACTCTGCCCACCTCTCTCATGCTGAATCACATCCATGGTGAGCATT 2700  
-----  
1741 CACTGCATTTCCCCACTCTGCCCACCTCTCTCATGCTGAATCACATCCATGGTGAGCATT 1800

2590 TTGATGGACAAAGTGGCACATCCAGTGGAGCGGTGGTAGATCCTGATAGACATGGGGCTC 2649  
2701 TTGATGGACAAAGTGGCACATCCAGTGGAGCGGTGGTAGATCCTGATAGACATGGGGCTC 2760  
-----  
1801 TTGATGGACAAAGTGGCACATCCAGTGGAGCGGTGGTAGATCCTGATAGACATGGGGCTC 1860

2650 CTGGGAGTAGAGAGACACACTAACAGCCACACCCTCTGGAAATCTGATACAGTAAATATA 2709  
2761 CTGGGAGTAGAGAGACACACTAACAGCCACACCCTCTGGAAATCTGATACAGTAAATATA 2820  
-----  
1861 CTGGGAGTAGAGAGACACACTAACAGCCACACCCTCTGGAAATCTGATACAGTAAATATA 1920

2710 TGA CTGCACCAGAAATATGTGAAATAGCAGACATTCTGCTTACTCATGTCTCCTTCCACA 2769  
2821 TGA CTGCACCAGAAA 2880  
-----  
1921 TGA CTGCACCAGAAAAAAAAAAAAAAAAAAAAA 1952

19/20

## Figure 8 continued

2770 GTTACTTCCTCGCTCCCTTTGCATCTAAACCTTTCTTCTTCCCAACTTATTGCCTGTA 2829  
2881 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA----- 2915  
-----  
-----

2830 GTCAGACCTGCTGTACAACCTATTTCTCTTCTCTTGAATGTCTTCCAGTGGCTGGAA 2889  
-----  
-----  
-----

2890 AGGTCCTCTGTGGTTATCTGTTAGAACAGTCTCTGTACACAATTCCTCCTAAAAACATC 2949  
-----  
-----  
-----

2950 CTTTTTTAAAAAAGAATTGTTAGCCATAAAGAAAGAACAAGATCATGCCCTTTGCAGG 3009  
-----  
-----  
-----

3010 GACATGGATGGAGCTGGAGGCCATTATCCTTCATAAACTATTGCAGGAACAGAAAACCAA 3069  
-----  
-----  
-----

3070 ACACTCCATATTCTCACTTGTAAGTGGGAGCTAAGTGAGAACACGTGGACACATAGAGGG 3129  
-----  
-----  
-----

3130 AAACAACACACACTGGGGCCTATGAGAGGGCGGAAGGTGGGAGGAGGGAGAGATCAGGAA 3189  
-----  
-----  
-----

3190 AAATAACTAATGGATACTTAGGGTGATGAAATAATCTGTGTAACAAACCCCATGACACA 3249  
-----  
-----  
-----

3250 CCTTTATGTATGTAACAAACCAGCACTTCCTGCGCATGTACCCCTGAACTTAAAAGTTAA 3309  
-----  
-----  
-----

20/20

**Figure 8 continued**

3310 AAAAAAGTTGAACTTAAAAATAACAGATTGGCCCATGCCAATCAAAGTATAATAGAAAGC 3369

-----  
-----  
-----

3370 ATAGTATAC 3378

-----  
-----  
-----

Express Mail Label No.

Page 1 of 4

Docket No.55908 (46322)

## Declaration and Power of Attorney for Patent Application English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"GLYCOSYL PHOSPHATIDYL INOSITOL SPECIFIC PHOSPHOLIPASE D PROTEINS AND USES THEREOF"

the specification of which

(check one)

☐ is attached hereto.  
☒ was filed on June 22, 2001 as United States Application No. or PCT  
Application No. 09/868,879  
 and was amended on \_\_\_\_\_  
 (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			Priority Not Claimed
PCT/GB99/04399	PCT	23 December 1999	
WO 00/39285			[ ]
(Number)	(Country)	(Day/Month/Year Filed)	
9828712.1	Great Britain	24 December 1998	
(Number)	(Country)	(Day/Month/Year Filed)	[ ]
9828715.4	Great Britain	24 December 1998	
9828713.9	Great Britain	24 December 1998	
(Number)	(Country)	(Day/Month/Year Filed)	[ ]



I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

_____ (Application Serial No.)	_____ (Filing Date)
_____ (Application Serial No.)	_____ (Filing Date)
_____ (Application Serial No.)	_____ (Filing Date)

I hereby claim the benefit under 35 U.S.C. Section 120 of the United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark office all information known to me to be material to patentability as defined in Title 37, C.F.C., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

PCT/GB99/04399 WO 00/39285 _____ (Application Serial No.)	23 December 1999 _____ (Filing Date)	pending _____ (Status) (patented, pending, abandoned)
_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)
_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

David G. Conlin	Reg. No. 27,026
George W. Neuner	Reg. No. 26,964
Linda M. Buckley	Reg. No. 31,003
Peter J. Manus	Reg. No. 26,766
Peter F. Corless	Reg. No. 33,860
Cara Z. Lowen	Reg. No. 38,227
William J. Daley, Jr.	Reg. No. 35,487
Christine C. O'Day	Reg. No. 38,256
Robert L. Buchanan	Reg. No. 40,927
David E. Tucker	Reg. No. 27,840
Lisa Swiszc Hazzard	Reg. No. 44,368

(11)


Send Correspondence to:

Robert L. Buchanan, Reg. No. 40,927  
 Edwards & Angell, LLP  
 101 Federal Street  
 Boston, Massachusetts 02210-1800  
 USA

Direct Telephone Calls to:  
 (name and telephone number)


Telephone: (617) 439-4444  
 Facsimile: (617) 439-4170

1-00

Full name of sole or first inventor Julian SCHOFIELD	
Sole or first inventor's signature 	Date: 3/06/01
Residence London, England GBN	
Citizenship Great Britain	
Post Office Address 59 Moorgreen House, Wynyatt Street, London EC1V 7JA, England	

→

200

Full name of second inventor, if any Thomas William RADEMACHER	
Second inventor's signature 	Date: 7/06/01
Residence Oxford, England GBN	
Citizenship <del>Great Britain</del> USA	
Post Office Address Foxcombe, The Ridgeway, Boars Hill, Oxford OX1 5EY, England	

Full name of third inventor, if any	
Third inventor's signature	Date:
Residence	
Citizenship	
Post Office Address	

Full name of fourth inventor, if any	
Fourth inventor's signature	Date:
Residence	
Citizenship	
Post Office Address	

#168674